1
|
Hacioglu C, Tuncer C. Boric acid Increases Susceptibility to Chemotherapy by Targeting the Ferritinophagy Signaling Pathway in TMZ Resistant Glioblastoma Cells. Biol Trace Elem Res 2024; 202:3574-3587. [PMID: 37906374 DOI: 10.1007/s12011-023-03930-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 10/22/2023] [Indexed: 11/02/2023]
Abstract
Glioblastoma (GBM) is a common and highly lethal form of brain cancer. Temozolomide (TMZ) is the primary chemotherapy used for GBM, but it has limited effectiveness, with about half of the patients developing resistance. Iron regulatory proteins (IRPs) modulate genes involved in iron metabolism, while the nuclear receptor coactivator 4 (NCOA4) controls iron metabolism through a process called ferritinophagy. In this study, we investigated whether boric acid increases chemosensitivity mediated by ferritinophagy via the NCOA4 and IRP2 signaling pathways in TMZ-resistant GBM cells. First, we generated TMZ-resistant GBM cells (A172-R and T98G-R cells). Next, we investigated the effects of boric acid on cell viability, proliferation, cell cycle, and cell morphology in these cells. Additionally, following boric acid treatment, we analyzed the expression and protein levels of various biochemical markers in these cells. Boric acid treatment in A172-R and T98G-R cells suppressed cell viability and proliferation, arrested these cells in the G1/G0 cell cycle, and induced morphological differences. Boric acid increased NCOA4, IRP2, iron, and malondialdehyde (MDA) levels in A172-R and T98G-R cells, while glutathione (GSH) and glutathione peroxidase 4 (GPx4) levels decreased. Moreover, boric acid treatment increased intracellular iron levels and lipid peroxidation by inducing NCOA4 and IRP2 expression levels in TMZ-resistant cells. According to our results, boric acid may regulate chemosensitivity in A172-R and T98G-R cells mediated by NCOA4 and IRP2. In conclusion, the manipulative effects of boric acid on the ferritinophagy pathway hold the potential to sensitize TMZ-resistant GBM cells to chemotherapy.
Collapse
Affiliation(s)
- Ceyhan Hacioglu
- Faculty of Pharmacy, Department of Biochemistry, Düzce University, Düzce, Turkey.
- Faculty of Medicine, Department of Medical Biochemistry, Düzce University, Düzce, Turkey.
| | - Cengiz Tuncer
- Faculty of Medicine, Department of Neurosurgery, Düzce University, Düzce, Turkey
| |
Collapse
|
2
|
Shen S, Wang S, Zhou D, Wu X, Gao M, Wu J, Yang Y, Pan X, Wang N. A clinician's perspective on boron neutron capture therapy: promising advances, ongoing trials, and future outlook. Int J Radiat Biol 2024:1-17. [PMID: 38986056 DOI: 10.1080/09553002.2024.2373746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Accepted: 06/13/2024] [Indexed: 07/12/2024]
Abstract
PURPOSE This comprehensive review aims to provide a unique clinical perspective on the latest advances and ongoing boron neutron capture therapy (BNCT) trials for various cancers. METHODS We critically analyzed clinical data from BNCT trials for head and neck cancer, glioblastoma, melanoma, meningioma, breast cancer, and liver tumors. We investigated differences in tumor responses and normal tissue toxicities among trials and discussed potential contributing factors. We also identified the limitations of early BNCT trials and proposed strategies to optimize future trial design. RESULTS BNCT has shown promising results in treating head and neck cancer, with high response rates and improved survival in patients with recurrent disease. In glioblastoma, BNCT combined with surgery and chemotherapy has demonstrated survival benefits compared to standard treatments. BNCT has also been successfully used for recurrent high-grade meningiomas and shows potential for melanomas, extramammary Paget's disease, and liver tumors. However, differences in tumor responses and toxicities were observed among trials, potentially attributable to variations in treatment protocols, patient characteristics, and evaluation methods. CONCLUSIONS BNCT is a promising targeted radiotherapy for various cancers. Further optimization and well-designed randomized controlled trials are needed to establish its efficacy and safety. Future studies should focus on standardizing treatment protocols and addressing limitations to guide clinical decision-making and research priorities.
Collapse
Affiliation(s)
- Shumin Shen
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Shanghu Wang
- Department of Radiotherapy, Anhui Chest Hospital, Hefei, China
| | - Dachen Zhou
- Department of General Surgery, The Second Hospital of Anhui Medical University, Hefei, China
| | - Xiuwei Wu
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Mingzhu Gao
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Jinjin Wu
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Yucai Yang
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Xiaoxi Pan
- Department of Nuclear Medicine, The Second Hospital of Anhui Medical University, Hefei, China
| | - Nianfei Wang
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| |
Collapse
|
3
|
Chen J, Li Y, Gan X, Weng C, Fang X, Liu G. Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy. Med Oncol 2024; 41:104. [PMID: 38573420 DOI: 10.1007/s12032-024-02351-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 03/04/2024] [Indexed: 04/05/2024]
Abstract
It has been proposed that boron neutron capture therapy (BNCT) holds promise as a treatment modality for melanoma. However, the effectiveness of boron agents in delivery remains a critical issue to be addressed for BNCT. To this end, phenylboronic acid, which exhibits good water solubility and low cytotoxicity similar to BPA, has been investigated as a potential nuclear-targeting boron agent. The boron concentration of phenylboronic acid was found to be 74.47 ± 12.17 ng/106 B16F10 cells and 45.77 ± 5.64 ng/106 cells in the nuclei. Molecular docking experiments were conducted to investigate the binding of phenylboronic acid to importin proteins involved in nuclear transport. The potential of phenylboronic acid to serve as a desirable nucleus-delivery boron agent for neutron capture therapy in melanoma warrants further exploration.
Collapse
Affiliation(s)
- Jiejian Chen
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Yonghao Li
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Xiaoning Gan
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Chengyin Weng
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Xisheng Fang
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Guolong Liu
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China.
| |
Collapse
|
4
|
Postuma I, Magni C, Marcaccio B, Fatemi S, Vercesi V, Ciocca M, Magro G, Orlandi E, Vischioni B, Ronchi S, Liu YH, Han Y, Geng C, González SJ, Bortolussi S. Using the photon isoeffective dose formalism to compare and combine BNCT and CIRT in a head and neck tumour. Sci Rep 2024; 14:418. [PMID: 38172585 PMCID: PMC10764928 DOI: 10.1038/s41598-023-50522-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Accepted: 12/20/2023] [Indexed: 01/05/2024] Open
Abstract
Boron Neutron Capture Therapy (BNCT) is a radiotherapy technique based on the enrichment of tumour cells with suitable 10-boron concentration and on subsequent neutron irradiation. Low-energy neutron irradiation produces a localized deposition of radiation dose caused by boron neutron capture reactions. Boron is vehiculated into tumour cells via proper borated formulations, able to accumulate in the malignancy more than in normal tissues. The neutron capture releases two high-LET charged particles (i.e., an alpha particle and a lithium ion), losing their energy in a distance comparable to the average dimension of one cell. Thus BNCT is selective at the cell level and characterized by high biological effectiveness. As the radiation field is due to the interaction of neutrons with the components of biological tissues and with boron, the dosimetry requires a formalism to express the absorbed dose into photon-equivalent units. This work analyzes a clinical case of an adenoid cystic carcinoma treated with carbon-ion radiotherapy (CIRT), located close to optic nerve and deep-seated as a practical example of how to apply the formalism of BNCT photon isoeffective dose and how to evaluate the BNCT dose distribution against CIRT. The example allows presenting different dosimetrical and radiobiological quantities and drawing conclusions on the potential of BNCT stemming on the clinical result of the CIRT. The patient received CIRT with a dose constraint on the optic nerve, affecting the peripheral part of the Planning Target Volume (PTV). After the treatment, the tumour recurred in this low-dose region. BNCT was simulated for the primary tumour, with the goal to calculate the dose distribution in isoeffective units and a Tumour Control Probability (TCP) to be compared with the one of the original treatment. BNCT was then evaluated for the recurrence in the underdosed region which was not optimally covered by charged particles due to the proximity of the optic nerve. Finally, a combined treatment consisting in BNCT and carbon ion therapy was considered to show the consistency and the potential of the model. For the primary tumour, the photon isoeffective dose distribution due to BNCT was evaluated and the resulted TCP was higher than that obtained for the CIRT. The formalism produced values that are consistent with those of carbon-ion. For the recurrence, BNCT dosimetry produces a similar TCP than that of primary tumour. A combined treatment was finally simulated, showing a TCP comparable to the BNCT-alone with overall dosimetric advantage in the most peripheral parts of the treatment volume. Isoeffective dose formalism is a robust tool to analyze BNCT dosimetry and to compare it with the photon-equivalent dose calculated for carbon-ion treatment. This study introduces for the first time the possibility to combine the dosimetry obtained by two different treatment modalities, showing the potential of exploiting the cellular targeting of BNCT combined with the precision of charged particles in delivering an homogeneous dose distribution in deep-seated tumours.
Collapse
Affiliation(s)
- Ian Postuma
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
| | - Chiara Magni
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
- Department of Physics, University of Pavia, Pavia, 27100, Italy
| | - Barbara Marcaccio
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
- Department of Physics, University of Pavia, Pavia, 27100, Italy
- National University of San Martín, Dan Beninson Institute, Buenos Aires, Argentina
| | - Setareh Fatemi
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
| | - Valerio Vercesi
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
| | - Mario Ciocca
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Giuseppe Magro
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Ester Orlandi
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Barbara Vischioni
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Sara Ronchi
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Yuan-Hao Liu
- Neuboron Medtech Ltd, Nanjing, China
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, NUAA, Nanjing, China
| | - Yang Han
- Department of Physics, University of Pavia, Pavia, 27100, Italy
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, NUAA, Nanjing, China
| | - Changran Geng
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, NUAA, Nanjing, China
| | - Sara Josefina González
- National University of San Martín, Dan Beninson Institute, Buenos Aires, Argentina
- National Atomic Energy Commission, CNEA, Buenos Aires, Argentina
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Silva Bortolussi
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy.
- Department of Physics, University of Pavia, Pavia, 27100, Italy.
| |
Collapse
|
5
|
Dana PM, Hallajzadeh J, Asemi Z, Mansournia MA, Yousefi B. Advances in Chitosan-based Drug Delivery Systems in Melanoma: A Narrative Review. Curr Med Chem 2024; 31:3488-3501. [PMID: 37202890 DOI: 10.2174/0929867330666230518143654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 03/24/2023] [Accepted: 04/10/2023] [Indexed: 05/20/2023]
Abstract
Melanoma accounts for the minority of skin cancer cases. However, it has the highest mortality rate among the subtypes of skin cancer. At the early stages of the disease, patients show a good prognosis after the surgery, but developing metastases leads to a remarkable drop in patients' 5-year survival rate. Despite the advances made in the therapeutic approaches to this disease, melanoma treatment is still facing several obstacles. Systemic toxicity, water insolubility, instability, lack of proper biodistribution, inadequate cellular penetration, and rapid clearance are some of the challenges that should be addressed in the field of melanoma treatment. While various delivery systems have been developed to circumvent these challenges, chitosan-based delivery platforms have indicated significant success. Chitosan that is produced by the deacetylation of chitin can be formulated into different materials (e.g., nanoparticle, film, and hydrogel) due to its characteristics. Both in vitro and in vivo studies have reported that chitosan-based materials can be used in drug delivery systems while offering a solution for the common problems in this area, such as enhancing biodistribution and skin penetration as well as the sustained release of the drugs. Herein, we reviewed the studies concerning the role of chitosan as a drug delivery system in melanoma and discussed how these drug systems are used for delivering chemotherapeutic drugs (e.g., doxorubicin and paclitaxel), genes (e.g., TRAIL), and RNAs (e.g., miRNA199a and STAT3 siRNA) successfully. Furthermore, we take a look into the role of chitosan-based nanoparticles in neutron capture therapy.
Collapse
Affiliation(s)
- Parisa Maleki Dana
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R. Iran
| | - Jamal Hallajzadeh
- Department of Biochemistry and Nutrition, Research Center for Evidence-based Health Management, Maragheh University of Medical Sciences, Maragheh, Iran
| | - Zatollah Asemi
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R. Iran
| | - Mohammad Ali Mansournia
- Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Bahman Yousefi
- Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
- Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
6
|
Lan KW, Huang WY, Chiu YL, Hsu FT, Chien YC, Hsiau YY, Wang TW, Keng PY. In vivo investigation of boron-rich nanodrugs for treating triple-negative breast cancers via boron neutron capture therapy. BIOMATERIALS ADVANCES 2023; 155:213699. [PMID: 37979440 DOI: 10.1016/j.bioadv.2023.213699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 11/03/2023] [Accepted: 11/06/2023] [Indexed: 11/20/2023]
Abstract
Triple-negative breast cancer (TNBC) is characterized by highly proliferative cancer cells and is the only subtype of breast cancer that lacks a targeted therapy. Boron neutron capture therapy (BNCT) is an approach that combines chemotherapy with radiotherapy and can potentially offer beneficial targeted treatment for TNBC patients owing to its unique ability to eradicate cancer cells selectively while minimizing damage to the surrounding healthy cells. Since BNCT relies on specific delivery of a high loading of B10 to the tumor site, there is growing research interest to develop more potent boron-based drugs for BNCT that can overcome the limitations of small-molecule boron compounds. In this study, polyethylene-glycol-coated boron carbon oxynitride nanoparticles (PEG@BCNO) of size 134.2±23.6nm were prepared as a promising drug for BNCT owing to their high boron content and enhanced biocompatibility. The therapeutic efficiency of PEG@BCNO was compared with a state-of-the-art 10BPA boron drug in mice bearing MDA-MB-231 tumor. In the orthotopic mouse model, PEG@BCNO showed higher B10 accumulation in the tumor tissues (6 μg 10B/g tissue compared to 3 μg 10B/g tissue in mice administered B10-enriched 10BPA drug) despite using the naturally occurring 11B/10B boron precursor in the preparation of the BCNO nanoparticles. The in vivo biodistribution of PEG@BCNO in mice bearing MDA-MB-231 showed a tumor/blood ratio of ~3.5, which is comparable to that of the state-of-the-art 10BPA-fructose drug. We further demonstrated that upon neutron irradiation, the mice bearing MDA-MB-231 tumor cells treated with PEG@BCNO and 10BPA showed tumor growth delay times of 9 days and 1 day, respectively, compared to mice in the control group after BNCT. The doubling times (DTs) for mice treated with PEG@BCNO and 10BPA as well as mice in the control group were calculated to be 31.5, 19.8, and 17.7 days, respectively. Immunohistochemical staining for the p53 and caspase-3 antibodies revealed that mice treated with PEG@BCNO showed lower probability of cancer recurrence and greater level of cellular apoptosis than mice treated with 10BPA and mice in the control group. Our study thus demonstrates the potential of pegylated BCNO nanoparticles in effectively inhibiting the growth of TNBC tumors compared to the state-of-the-art boron drug 10BPA.
Collapse
Affiliation(s)
- Kai-Wei Lan
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan, ROC
| | - Wei-Yuan Huang
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan, ROC
| | - Yi-Lin Chiu
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan, ROC
| | - Fang-Tzu Hsu
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan, ROC
| | - Yun-Chen Chien
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan, ROC
| | - Yong-Yun Hsiau
- College of Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan, ROC
| | - Tzu-Wei Wang
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan, ROC
| | - Pei Yuin Keng
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan, ROC.
| |
Collapse
|
7
|
Järvinen J, Pulkkinen H, Rautio J, Timonen JM. Amino Acid-Based Boron Carriers in Boron Neutron Capture Therapy (BNCT). Pharmaceutics 2023; 15:2663. [PMID: 38140004 PMCID: PMC10748186 DOI: 10.3390/pharmaceutics15122663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Revised: 11/18/2023] [Accepted: 11/21/2023] [Indexed: 12/24/2023] Open
Abstract
Interest in the design of boronated amino acids has emerged, partly due to the utilization of boronophenylalanine (BPA), one of the two agents employed in clinical Boron Neutron Capture Therapy (BNCT). The boronated amino acids synthesized thus far for BNCT investigations can be classified into two categories based on the source of boron: boronic acids or carboranes. Amino acid-based boron carriers, employed in the context of BNCT treatment, demonstrate significant potential in the treatment of challenging tumors, such as those located in the brain. This review aims to shed light on the developmental journey and challenges encountered over the years in the field of amino acid-based boron delivery compound development. The primary focus centers on the utilization of the large amino acid transporter 1 (LAT1) as a target for boron carriers in BNCT. The development of efficient carriers remains a critical objective, addressing challenges related to tumor specificity, effective boron delivery, and rapid clearance from normal tissue and blood. LAT1 presents an intriguing and promising target for boron delivery, given its numerous characteristics that make it well suited for drug delivery into tumor tissues, particularly in the case of brain tumors.
Collapse
Affiliation(s)
- Juulia Järvinen
- School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| | - Herkko Pulkkinen
- Department of Technical Physics, Faculty of Science, Forestry and Technology, University of Eastern Finland, 70211 Kuopio, Finland
| | - Jarkko Rautio
- School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| | - Juri M. Timonen
- School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, P.O. Box 56, 00014 Helsinki, Finland
| |
Collapse
|
8
|
Chang CH, Chen CJ, Yu CF, Tsai HY, Chen FH, Chiang CS. Targeting M-MDSCs enhances the therapeutic effect of BNCT in the 4-NQO-induced murine head and neck squamous cell carcinoma model. Front Oncol 2023; 13:1263873. [PMID: 37886177 PMCID: PMC10598372 DOI: 10.3389/fonc.2023.1263873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 09/15/2023] [Indexed: 10/28/2023] Open
Abstract
Purpose Malignant head and neck squamous cell carcinoma (HNSCC) is characterized by a poor prognosis and resistance to conventional radiotherapy. Infiltrating myeloid-derived suppressive cells (MDSCs) is prominent in HNSCC and is linked to immune suppression and tumor aggressiveness. This study aimed to investigate the impact of boron neutron capture therapy (BNCT) on the MDSCs in the tumor microenvironment and peripheral blood and to explore the potential for MDSCs depletion combined with BNCT to reactivate antitumor immunity. Methods and materials Carcinogen, 4-NQO, -induced oral tumors were irradiated with a total physical dose of 2 Gy BNCT in Tsing Hua Open Reactor (THOR). Flow cytometry and immunohistochemistry accessed the dynamics of peripheral MDSCs and infiltrated MDSCs within the tumor microenvironment. Mice were injected with an inhibitor of CSF-1 receptor (CSF-1R), PLX3397, to determine whether modulating M-MDSCs could affect mice survival after BNCT. Results Peripheral CD11b+Ly6ChighLy6G- monocytic-MDSCs (M-MDSCs), but not CD11b+Ly6CloLy6Ghigh polymorphonuclear-MDSCs (PMN-MDSCs), increased as tumor progression. After BNCT treatment, there were temporarily decreased and persistent increases of M-MDSCs thereafter, either in peripheral blood or in tumors. The administration of PLX-3397 hindered BNCT-caused M-MDSCs infiltration, prolonged mice survival, and activated tumor immunity by decreasing tumor-associated macrophages (TAMs) and increasing CD8+ T cells. Conclusion M-MDSCs were recruited into 4-NQO-induced tumors after BNCT, and their number was also increased in peripheral blood. Assessment of M-MDSCs levels in peripheral blood could be an index to determine the optimal intervention window. Their temporal alteration suggests an association with tumor recurrence after BNCT, making M-MDSCs a potential intervention target. Our preliminary results showed that PLX-3397 had strong M-MDSCs, TAMs, and TIL (tumor-infiltrating lymphocyte) modulating effects that could synergize tumor control when combined with BNCT.
Collapse
Affiliation(s)
- Chun-Hsiang Chang
- Department of Biomedical Engineering and Environment Sciences, National Tsing Hua University, Hsinchu, Taiwan
| | - Chi-Jui Chen
- Department of Biomedical Engineering and Environment Sciences, National Tsing Hua University, Hsinchu, Taiwan
| | - Ching-Fang Yu
- Institute for Radiological Research, Chang Gung University, Taoyuan, Taiwan
- Department of Radiation Oncology, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan
| | - Hui-Yu Tsai
- Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu, Taiwan
| | - Fang-Hsin Chen
- Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu, Taiwan
| | - Chi-Shiun Chiang
- Department of Biomedical Engineering and Environment Sciences, National Tsing Hua University, Hsinchu, Taiwan
- Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu, Taiwan
| |
Collapse
|
9
|
Teng YC, Chen J, Zhong WB, Liu YH. Correcting for the heterogeneous boron distribution in a tumor for BNCT dose calculation. Sci Rep 2023; 13:15741. [PMID: 37735579 PMCID: PMC10514037 DOI: 10.1038/s41598-023-42284-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 09/07/2023] [Indexed: 09/23/2023] Open
Abstract
Most treatment planning systems of boron neutron capture therapy perform dose calculations based on the assumption of a homogeneous boron distribution in tumors, which leads to dose distortion due to the difference between the tumor-to-normal tissue ratio (TNR) range measured in positron emission tomography images (PET) and the target delineation in computed tomography images of the treatment plan. The heterogeneous boron distribution in the target of the treatment plan can be obtained by image fusion. This study provides a way to quantify a heterogeneous boron distribution based on PET images. Theoretically, the same mean TNR for dose calculation by homogeneous or heterogeneous boron distribution should get almost the same mean dose. However, slightly different mean doses are found due to the partial volume effect for a small target volume. The wider the boron distribution is, the higher the impact on the dose-volume histogram distribution is. Dose distribution with homogeneous boron distribution may be overestimated in low boron uptake regions by wrong boron concentration and neutron flux depression. To accurately give the tumor prescription dose and achieve better tumor control, for low dose regions of the tumor should be considered more boron neutron capture therapy treatments or combined with other treatment modalities. The heterogeneous boron distribution must be taken into consideration to have an accurate dose estimation. Therefore, the way how medical physicists and clinicians process the TNR in gross tumor volume should be refined, and the method demonstrated in the work provides a good reference.
Collapse
Affiliation(s)
- Yi-Chiao Teng
- Neuboron Therapy System Ltd., Xiamen, Fujian Province, People's Republic of China
- National Tsing Hua University, Hsinchu, 30013, Taiwan, Republic of China
| | - Jiang Chen
- Neuboron Therapy System Ltd., Xiamen, Fujian Province, People's Republic of China
- Nanjing Vocational University of Industry Technology, Nanjing, Jiangsu Province, People's Republic of China
| | - Wan-Bing Zhong
- Neuboron Therapy System Ltd., Xiamen, Fujian Province, People's Republic of China
| | - Yuan-Hao Liu
- Neuboron Therapy System Ltd., Xiamen, Fujian Province, People's Republic of China.
- Nanjing University of Aeronautics and Astronautics, Nanjing, Jiangsu Province, People's Republic of China.
- Neuboron Medtech Ltd., Nanjing, Jiangsu Province, People's Republic of China.
- Xiamen Humanity Hospital, Xiamen, Fujian Province, People's Republic of China.
| |
Collapse
|
10
|
Shanmugam M, Kuthala N, Kong X, Chiang CS, Hwang KC. Combined Gadolinium and Boron Neutron Capture Therapies for Eradication of Head-and-Neck Tumor Using Gd 10B 6 Nanoparticles under MRI/CT Image Guidance. JACS AU 2023; 3:2192-2205. [PMID: 37654578 PMCID: PMC10466345 DOI: 10.1021/jacsau.3c00250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 07/16/2023] [Accepted: 07/26/2023] [Indexed: 09/02/2023]
Abstract
Eradication of head-and-neck (H&N) tumors is very difficult and challenging because of the characteristic feature of frequent recurrence and the difficulty in killing cancer stem cells. Neutron capture therapy (NCT) is emerging as a noninvasive potential modality for treatments of various types of tumors. Herein, we report that 98.5% 10B-enriched anti-EGFR-Gd10B6 nanoparticles can not only deliver large doses of 158 μg 10B/g tumor tissues as well as 56.8 μg 157Gd/g tumor tissues with a very high tumor-to-blood (T/B) 10B ratio of 4.18, but also exert very effective CT/MRI image-guided combined GdBNCT effects on killing cancer stem cells and eradication of recurrent head-and-neck (H&N) tumors. This leads to a long average half-lifespan of 81 days for H&N tumor-bearing mice, which is a record-making result, and surpasses the best result reported in the literature using combined radiotherapy and T cell-mediated immunotherapy (70 d).
Collapse
Affiliation(s)
- Munusamy Shanmugam
- Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan ROC
| | - Naresh Kuthala
- Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan ROC
| | - Xiangyi Kong
- Department
of Breast Surgical Oncology, National Cancer Center/National Clinical
Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Chi-Shiun Chiang
- Department
of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan R.O.C.
| | - Kuo Chu Hwang
- Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan ROC
| |
Collapse
|
11
|
Monti Hughes A, Hu N. Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies. Cancers (Basel) 2023; 15:4091. [PMID: 37627119 PMCID: PMC10452654 DOI: 10.3390/cancers15164091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 07/27/2023] [Accepted: 07/31/2023] [Indexed: 08/27/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed, in this review, those articles published between 2020 and 2023 reporting new boron compounds and strategies that were proved therapeutically useful in in vitro and/or in vivo radiobiological studies, a critical step for translation to a clinical setting. We also explored new pathologies that could potentially be treated with BNCT and newly developed theranostic boron agents. All these radiobiological advances intend to solve those limitations and questions that arise during patient treatment in the clinical field, with BNCT and other therapies. In this sense, active communication between clinicians, radiobiologists, and all disciplines will improve BNCT for cancer patients, in a cost- and time-effective way.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Radiation Pathology Division, Department Radiobiology, National Atomic Energy Commission, San Martín, Buenos Aires B1650KNA, Argentina
- National Scientific and Technical Research Council, Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan;
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan
| |
Collapse
|
12
|
Kanygin V, Zaboronok A, Kichigin A, Petrova E, Guselnikova T, Kozlov A, Lukichev D, Mathis BJ, Taskaev S. Gadolinium Neutron Capture Therapy for Cats and Dogs with Spontaneous Tumors Using Gd-DTPA. Vet Sci 2023; 10:vetsci10040274. [PMID: 37104429 PMCID: PMC10142813 DOI: 10.3390/vetsci10040274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 03/20/2023] [Accepted: 03/30/2023] [Indexed: 04/08/2023] Open
Abstract
We conducted a clinical veterinary study on neutron capture therapy (NCT) at a neutron-producing accelerator with seven incurable pets with spontaneous tumors and gadolinium as a neutron capture agent (gadolinium neutron capture therapy, or GdNCT). Gadolinium-containing dimeglumine gadopentetate, or Gd-DTPA (Magnevist®, 0.6 mL/kg b.w.), was used. We observed mild and reversible toxicity related to the treatment. However, no significant tumor regression in response to the treatment was observed. In most cases, there was continued tumor growth. Overall clinical improvement after treatment was only temporary. The use of Gd-DTPA for NCT had no significant effects on the life expectancy and quality of life of animals with spontaneous tumors. Further experiments using more advanced gadolinium compounds are needed to improve the effect of GdNCT so that it can become an alternative to boron neutron capture therapy. Such studies are also necessary for further NCT implementation in clinical practice as well as in veterinary medicine.
Collapse
Affiliation(s)
- Vladimir Kanygin
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, ave. Lavrentiev, 11, 630090 Novosibirsk, Russia
- Laboratory of Nuclear and Innovative Medicine, Department of Physics, Novosibirsk State University, Pirogov str., 1, 630090 Novosibirsk, Russia
| | - Alexander Zaboronok
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba 305-8575, Ibaraki, Japan
| | - Aleksandr Kichigin
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, ave. Lavrentiev, 11, 630090 Novosibirsk, Russia
- Laboratory of Nuclear and Innovative Medicine, Department of Physics, Novosibirsk State University, Pirogov str., 1, 630090 Novosibirsk, Russia
| | - Elena Petrova
- Veterinary Clinic “Best”, Frunze str., 57, 630005 Novosibirsk, Russia
| | - Tatyana Guselnikova
- Laboratory of Nuclear and Innovative Medicine, Department of Physics, Novosibirsk State University, Pirogov str., 1, 630090 Novosibirsk, Russia
- Nikolaev Institute of Inorganic Chemistry, Siberian Branch of Russian Academy of Sciences, ave. Lavrentiev, 3, 630090 Novosibirsk, Russia
| | - Andrey Kozlov
- Clinical Hospital “Avicenna”, Uritskogo str., 2, 630007 Novosibirsk, Russia
| | - Dmitriy Lukichev
- Laboratory of Nuclear and Innovative Medicine, Department of Physics, Novosibirsk State University, Pirogov str., 1, 630090 Novosibirsk, Russia
| | - Bryan J. Mathis
- International Medical Center, University of Tsukuba Hospital, Amakubo 2-1-1, Tsukuba 305-8576, Ibaraki, Japan
| | - Sergey Taskaev
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, ave. Lavrentiev, 11, 630090 Novosibirsk, Russia
- Laboratory of Nuclear and Innovative Medicine, Department of Physics, Novosibirsk State University, Pirogov str., 1, 630090 Novosibirsk, Russia
| |
Collapse
|
13
|
Wittig A, Sauerwein WAG. Strategic Clinical Trial Design for Boron Neutron Capture Therapy. Cancer Biother Radiopharm 2023; 38:195-200. [PMID: 37023401 DOI: 10.1089/cbr.2022.0074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023] Open
Abstract
Boron neutron capture therapy (BNCT) involves infusion of cancer patients with a tumor-seeking, boron-loaded compound and irradiation by a beam of neutrons, with an energy range of 1 eV-10 keV. Neutron capture in the 10B atoms results in an effective lethal radiation dose to the tumor cells, while sparing the healthy tissue. Recently available accelerator-based irradiation facilities facilitate developing BNCT to a treatment modality. However, the binary principle of BNCT, together with other points, is challenging in designing clinical trials that allow a timely and safe introduction of this innovative targeted modality into clinical practice. We propose a methodological framework to work toward a systematic, coordinated, and internationally accepted and evidence-based approach.
Collapse
Affiliation(s)
- Andrea Wittig
- Department of Radiotherapy and Radiation Oncology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany
| | - Wolfgang A G Sauerwein
- Deutsche Gesellschaft für Bor-Neutroneneinfangtherapie (DGBNCT), Essen, Germany
- BNCT Global GmbH, Essen, Germany
| |
Collapse
|
14
|
Chan WJ, Bupphathong S, Cho HL, Goudar VS, Dehestani S, Chiang CS, Tseng FG. Engineering a potent boron-10-enriched polymeric nanoparticle for boron neutron capture therapy. Nanomedicine (Lond) 2023; 18:743-754. [PMID: 37306216 DOI: 10.2217/nnm-2022-0330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023] Open
Abstract
Background: Boron neutron capture therapy (BNCT) is a promising cancer treatment that eliminates tumor cells by triggering high-energy radiation within cancer cells. Aim: In vivo evaluation of poly(vinyl alcohol)/boric acid crosslinked nanoparticles (PVA/BA NPs) for BNCT. Materials & methods: PVA/BA NPs were synthesized and intravenously injected into tumor-bearing mice for BNCT. Results: The in vitro boron uptake of PVA/BA NPs in tumor cells was 70-fold higher than the required boron uptake for successful BNCT. In an in vivo study, PVA/BA NPs showed a 44.29% reduction in tumor size compared with clinically used boronophenylalanine for oral cancer in a murine model. Conclusion: PVA/BA NPs exhibited effective therapeutic results for oral cancer treatments in BNCT.
Collapse
Affiliation(s)
- Wei-Jen Chan
- Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Sasinan Bupphathong
- Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, Taiwan
| | - Han-Lin Cho
- Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, Taiwan
| | | | - Sina Dehestani
- Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Chi-Shiun Chiang
- Department of Biomedical Engineering & Environmental Sciences, National Tsing Hua University, Hsinchu City, 30013, Taiwan
| | - Fan-Gang Tseng
- Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, Taiwan
| |
Collapse
|
15
|
Kondo N, Takada S, Hagimori M, Temma T. Development of a 2-(2-Hydroxyphenyl)-1 H-benzimidazole-Based Fluorescence Sensor Targeting Boronic Acids for Versatile Application in Boron Neutron Capture Therapy. Cancers (Basel) 2023; 15:cancers15061862. [PMID: 36980747 PMCID: PMC10046934 DOI: 10.3390/cancers15061862] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Revised: 03/06/2023] [Accepted: 03/17/2023] [Indexed: 03/30/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is an attractive approach to treating cancers. Currently, only one 10B-labeled boronoagent (Borofalan, BPA) has been approved for clinical BNCT in Japan, and methods for predicting and measuring BNCT efficacy must be established to support the development of next-generation 10B-boronoagents. Fluorescence sensors targeting boronic acids can achieve this because the amount and localization of 10B in tumor tissues directly determine BNCT efficacy; however, current sensors are nonoptimal given their slow reaction rate and weak fluorescence (quantum yield < 0.1). Herein, we designed and synthesized a novel small molecular-weight fluorescence sensor, BITQ, targeting boronic acids. In vitro qualitative and quantitative properties of BITQ were assessed using a fluorophotometer and a fluorescence microscope together with BPA quantification in blood samples. BITQ exhibited significant quantitative and selective fluorescence after reacting with BPA (post-to-pre-fluorescence ratio = 5.6; quantum yield = 0.53); the fluorescence plateaued within 1 min after BPA mixing, enabling the visualization of intracellular BPA distribution. Furthermore, BITQ quantified the BPA concentration in mouse blood with reliability comparable with that of current methods. This study identifies BITQ as a versatile fluorescence sensor for analyzing boronic acid agents. BITQ will contribute to 10B-boronoagent development and promote research in BNCT.
Collapse
Affiliation(s)
- Naoya Kondo
- Department of Biofunctional Analysis, Graduate School of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki 569-1094, Osaka, Japan
| | - Shinya Takada
- Department of Biofunctional Analysis, Graduate School of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki 569-1094, Osaka, Japan
| | - Masayori Hagimori
- Laboratory of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien Kyubancho, Nishinomiya 663-8179, Hyogo, Japan
| | - Takashi Temma
- Department of Biofunctional Analysis, Graduate School of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki 569-1094, Osaka, Japan
| |
Collapse
|
16
|
Huang YS, Peir JJ, Wu CJ, Wang MY, Chen YW, Lee JC, Chou FI. NeuTHOR Station—A Novel Integrated Platform for Monitoring BNCT Clinical Treatment, Animal and Cell Irradiation Study at THOR. Life (Basel) 2023; 13:life13030800. [PMID: 36983956 PMCID: PMC10051313 DOI: 10.3390/life13030800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 02/23/2023] [Accepted: 03/14/2023] [Indexed: 03/18/2023] Open
Abstract
(1) Background: A well-established Boron Neutron Capture Therapy (BNCT) facility includes many essential systems, which are the epithermal neutron beam system, on-line monitoring system (OMS), QA/QC (quality assurance or quality control) system, boron concentration (BC) measurement system, and treatment planning system (TPS). Accurate data transmission, monitoring, and deposition among these systems are of vital importance before, during, and after clinical, animal, and cell BNCT irradiation. This work developed a novel integrated platform NeuTHOR Station (NeuTHORS) for BNCT at Tsing Hua Open-pool Reactor (THOR). Apart from the data of the OMS and QA/QC system, the data of BC and TPS can be loaded on NeuTHORS before BNCT clinical, animal, and cell irradiation. (2) Methods: A multi-paradigm computer programming language c# (c sharp) was used to develop the integrated platform NeuTHORS. The design of NeuTHORS is based on the standard procedures of BNCT treatment or experiment at THOR. Moreover, parallel testing with OMS-BNCT (the former OMS) and QA/QC of THOR was also performed for more than 70 times to verify the validation of NeuTHORS. (3) Results: According to the comparisons of the output, NeuTHORS and OMS-BNCT and QA/QC of THOR show very good consistency. NeuTHORS is now installed on an industrial PC (IPC) and successfully performs the monitoring of BNCT Treatment at THOR. Patients’ f BC and TPS data are also input into NeuTHORS and stored on IPC through an internal network from BC measurement room and TPS physicist. Therefore, the treatment data of each patient can be instantaneously established after each BNCT treatment for further study on BNCT. NeuTHORS can also be applied on data acquisition for a BNCT-related study, especially for animal or cell irradiation experiments. (4) Conclusions: A novel integrated platform NeuTHOR Station for monitoring BNCT clinical treatment and animal and cell irradiation study has been successfully established at THOR. With this platform, BNCT radiobiology investigations will be efficiently performed and a thorough data storage and analysis system of BNCT treatments or experiments can thus be systematically built up for the further investigation of BNCT at THOR.
Collapse
Affiliation(s)
- Yu-Shiang Huang
- Nuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu 300044, Taiwan
| | - Jinn-Jer Peir
- Nuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu 300044, Taiwan
- Correspondence: ; Tel.: +886-3-5742860
| | - Chuan-Jen Wu
- Nuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu 300044, Taiwan
| | - Mei-Ya Wang
- Nuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu 300044, Taiwan
| | - Yi-Wei Chen
- Department of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
- Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu 30015, Taiwan
| | - Jia-Cheng Lee
- Department of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
- Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu 30015, Taiwan
| | - Fong-In Chou
- Nuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu 300044, Taiwan
- Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu 300044, Taiwan
| |
Collapse
|
17
|
Matsubayashi N, Hu N, Takata T, Sasaki A, Mukawa T, Suga K, Sakurai Y, Tanaka H. Characteristics of optically stimulated luminescent dosimeter of beryllium oxide in BNCT irradiation field. RADIAT MEAS 2023. [DOI: 10.1016/j.radmeas.2023.106900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
18
|
Boumghar R, Belgaid M, Mazidi S, Segueni T, Sayah B. Feasibility study of using the NUR research reactor for a BNCT installation and Monte Carlo optimization of a BSA. NUCLEAR ENGINEERING AND DESIGN 2022. [DOI: 10.1016/j.nucengdes.2022.111948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Cheng X, Li F, Liang L. Boron Neutron Capture Therapy: Clinical Application and Research Progress. Curr Oncol 2022; 29:7868-7886. [PMID: 36290899 PMCID: PMC9601095 DOI: 10.3390/curroncol29100622] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Revised: 10/11/2022] [Accepted: 10/13/2022] [Indexed: 11/05/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary modality that is used to treat a variety of malignancies, using neutrons to irradiate boron-10 (10B) nuclei that have entered tumor cells to produce highly linear energy transfer (LET) alpha particles and recoil 7Li nuclei (10B [n, α] 7Li). Therefore, the most important part in BNCT is to selectively deliver a large number of 10B to tumor cells and only a small amount to normal tissue. So far, BNCT has been used in more than 2000 cases worldwide, and the efficacy of BNCT in the treatment of head and neck cancer, malignant meningioma, melanoma and hepatocellular carcinoma has been confirmed. We collected and collated clinical studies of second-generation boron delivery agents. The combination of different drugs, the mode of administration, and the combination of multiple treatments have an important impact on patient survival. We summarized the critical issues that must be addressed, with the hope that the next generation of boron delivery agents will overcome these challenges.
Collapse
Affiliation(s)
- Xiang Cheng
- Oncology Department, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei 230601, China
| | - Fanfan Li
- Oncology Department, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei 230601, China
- Correspondence: (F.L.); (L.L.); Tel.: +86-13855137365 (F.L.); +86-15905602477 (L.L.)
| | - Lizhen Liang
- Hefei Comprehensive National Science Center, Institute of Energy, Building 9, Binhu Excellence City Phase I, 16 Huayuan Avenue, Baohe District, Hefei 230031, China
- Correspondence: (F.L.); (L.L.); Tel.: +86-13855137365 (F.L.); +86-15905602477 (L.L.)
| |
Collapse
|
20
|
Monti Hughes A, Schwint AE. Animal Tumor Models for Boron Neutron Capture Therapy Studies (Excluding Central Nervous System Solid Tumors). Cancer Biother Radiopharm 2022. [PMID: 36130136 DOI: 10.1089/cbr.2022.0054] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Translational research in adequate experimental models is necessary to optimize boron neutron capture therapy (BNCT) for different pathologies. Multiple radiobiological in vivo studies have been performed in a wide variety of animal models, studying multiple boron compounds, routes of compound administration, and a range of administration strategies. Animal models are useful for the study of the stability and potential toxicity of new boron compounds or delivery systems, BNCT theranostic strategies, the evaluation of biomarkers to monitor BNCT therapeutic and adverse effects, and to study the BNCT immune response by the host against tumor cells. This article will mention examples of these studies, highlighting the importance of experimental animal models for the advancement of BNCT. Animal models are essential to design novel, safe, and effective clinical BNCT protocols for existing or new targets for BNCT.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Departamento de Radiobiología, Centro Atómico Constituyentes, Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Amanda E Schwint
- Departamento de Radiobiología, Centro Atómico Constituyentes, Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| |
Collapse
|
21
|
Seo IH, Lee J, Na D, Kyung H, Yang J, Lee S, Jeon SJ, Choi JW, Lee KY, Yi J, Han J, Yoo M, Kim SH. The Anti-Tumor Effect of Boron Neutron Capture Therapy in Glioblastoma Subcutaneous Xenograft Model Using the Proton Linear Accelerator-Based BNCT System in Korea. Life (Basel) 2022; 12:life12081264. [PMID: 36013445 PMCID: PMC9410173 DOI: 10.3390/life12081264] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 08/16/2022] [Accepted: 08/17/2022] [Indexed: 04/08/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a radiation therapy that selectively kills cancer cells and is being actively researched and developed around the world. In Korea, development of the proton linear accelerator-based BNCT system has completed development, and its anti-cancer effect in the U-87 MG subcutaneous xenograft model has been evaluated. To evaluate the efficacy of BNCT, we measured 10B-enriched boronophenylalanine (BPA) uptake in U-87 MG, FaDu, and SAS cells and evaluated cell viability by clonogenic assays. In addition, the boron concentration in the tumor, blood, and skin on the U-87 MG xenograft model was measured, and the tumor volume was measured for 4 weeks after BNCT. In vitro, the intracellular boron concentration was highest in the order of SAS, FaDu, and U-87 MG, and cell survival fractions decreased depending on the BPA treatment concentration and neutron irradiation dose. In vivo, the tumor volume was significantly decreased in the BNCT group compared to the control group. This study confirmed the anti-cancer effect of BNCT in the U-87 MG subcutaneous xenograft model. It is expected that the proton linear accelerator-based BNCT system developed in Korea will be a new option for radiation therapy for cancer treatment.
Collapse
Affiliation(s)
| | - Jeongwoo Lee
- A-BNCT Center, Dawonmedax, Incheon 21988, Korea
- Department of Pharmacy, ERICA Campus, Hanyang University, Ansan 15588, Korea
| | - Dasom Na
- A-BNCT Center, Dawonmedax, Incheon 21988, Korea
| | | | - Jieun Yang
- A-BNCT Center, Dawonmedax, Incheon 21988, Korea
| | | | | | | | | | - Jungyu Yi
- A-BNCT Center, Dawonmedax, Incheon 21988, Korea
- Department of Nuclear Engineering, Hanyang University, Seoul 04763, Korea
| | - Jaehwan Han
- A-BNCT Center, Dawonmedax, Incheon 21988, Korea
| | | | - Se Hyun Kim
- A-BNCT Center, Dawonmedax, Incheon 21988, Korea
- Correspondence: ; Tel.: +82-2-6251-4468
| |
Collapse
|
22
|
Monti Hughes A, Goldfinger JA, Palmieri MA, Ramos P, Santa Cruz IS, De Leo L, Garabalino MA, Thorp SI, Curotto P, Pozzi ECC, Kawai K, Sato S, Itoiz ME, Trivillin VA, Guidobono JS, Nakamura H, Schwint AE. Boron Neutron Capture Therapy (BNCT) Mediated by Maleimide-Functionalized Closo-Dodecaborate Albumin Conjugates (MID:BSA) for Oral Cancer: Biodistribution Studies and In Vivo BNCT in the Hamster Cheek Pouch Oral Cancer Model. LIFE (BASEL, SWITZERLAND) 2022; 12:life12071082. [PMID: 35888170 PMCID: PMC9323568 DOI: 10.3390/life12071082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 07/11/2022] [Accepted: 07/14/2022] [Indexed: 12/12/2022]
Abstract
Background: BNCT (Boron Neutron Capture Therapy) is a tumor-selective particle radiotherapy that combines preferential boron accumulation in tumors and neutron irradiation. Although p-boronophenylalanine (BPA) has been clinically used, new boron compounds are needed for the advancement of BNCT. Based on previous studies in colon tumor-bearing mice, in this study, we evaluated MID:BSA (maleimide-functionalized closo-dodecaborate conjugated to bovine serum albumin) biodistribution and MID:BSA/BNCT therapeutic effect on tumors and associated radiotoxicity in the hamster cheek pouch oral cancer model. Methods: Biodistribution studies were performed at 30 mg B/kg and 15 mg B/kg (12 h and 19 h post-administration). MID:BSA/BNCT (15 mg B/kg, 19 h) was performed at three different absorbed doses to precancerous tissue. Results: MID:BSA 30 mg B/kg protocol induced high BSA toxicity. MID:BSA 15 mg B/kg injected at a slow rate was well-tolerated and reached therapeutically useful boron concentration values in the tumor and tumor/normal tissue ratios. The 19 h protocol exhibited significantly lower boron concentration values in blood. MID:BSA/BNCT exhibited a significant tumor response vs. the control group with no significant radiotoxicity. Conclusions: MID:BSA/BNCT would be therapeutically useful to treat oral cancer. BSA toxicity is a consideration when injecting a compound conjugated to BSA and depends on the animal model studied.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
- National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
- Correspondence: or ; Tel.: +54-9-11-41689832 or +54-11-6772-7927
| | - Jessica A. Goldfinger
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Mónica A. Palmieri
- Biodiversity and Experimental Biology Department, School of Exact and Natural Sciences, University of Buenos Aires, Av. Int. Güiraldes 2160, 4° piso, Pab. II, Ciudad Autónoma de Buenos Aires C1428EGA, Argentina;
| | - Paula Ramos
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Iara S. Santa Cruz
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Luciana De Leo
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Marcela A. Garabalino
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Silvia I. Thorp
- Department of Instrumentation and Control, National Atomic Energy Commission, Presbítero Juan González y Aragon, 15, Ezeiza, Buenos Aires B1802AYA, Argentina;
| | - Paula Curotto
- Department of Research and Production Reactors, National Atomic Energy Commission, Presbítero Juan González y Aragon, 15, Ezeiza, Buenos Aires B1802AYA, Argentina; (P.C.); (E.C.C.P.)
| | - Emiliano C. C. Pozzi
- Department of Research and Production Reactors, National Atomic Energy Commission, Presbítero Juan González y Aragon, 15, Ezeiza, Buenos Aires B1802AYA, Argentina; (P.C.); (E.C.C.P.)
| | - Kazuki Kawai
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.K.); (S.S.); (H.N.)
| | - Shinichi Sato
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.K.); (S.S.); (H.N.)
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan
| | - María E. Itoiz
- Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, M.T. de Alvear 2142, Ciudad Autónoma de Buenos Aires C1122AAH, Argentina;
| | - Verónica A. Trivillin
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
- National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Juan S. Guidobono
- Buenos Aires Institute of Ecology, Genetics and Evolution (IEGEBA), CONICET, UBA, Intendente Güiraldes 2160, Ciudad Universitaria, Ciudad Autónoma de Buenos Aires C1428EGA, Argentina;
| | - Hiroyuki Nakamura
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.K.); (S.S.); (H.N.)
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan
| | - Amanda E. Schwint
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
- National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| |
Collapse
|
23
|
Tang F, Wei Y, Zhang S, Wang J, Gu W, Tang F, Peng X, Wei Y, Liu J, Chen W, Zhang S, Gu L, Li Y. Evaluation of Pharmacokinetics of Boronophenylalanine and Its Uptakes in Gastric Cancer. Front Oncol 2022; 12:925671. [PMID: 35903711 PMCID: PMC9314552 DOI: 10.3389/fonc.2022.925671] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 06/06/2022] [Indexed: 11/22/2022] Open
Abstract
Boron neutron capture therapy (BNCT), a cellular-level particle radiation therapy, combines boron compounds selectively delivered to tumor tissue with neutron irradiation. Boronophenylalanine (BPA) is a boron compound widely used in malignant melanoma, malignant brain tumors, and recurrent head and neck cancer. However, neither basic nor clinical research was reported for the treatment of gastric cancer using BPA. Selective distribution of boron in tumors rather than that in blood or normal tissue prior to neutron irradiation is required for the successful treatment of BNCT. This study evaluated the pharmacokinetics and safety of 10B-labeled BPA (10B-BPA, abbreviated as BPA) and its uptakes in gastric cancer. Pharmacokinetics and safety were evaluated in Sprague–Dawley (SD) rats intravenously injected with BPA. The uptakes of boron in gastric cancer cell line MKN45 and in cell-derived xenografts (CDX) and patient-derived xenografts (PDX) animal models were measured. The results showed that the boron concentration in the blood of rats decreased fast in the first 30 min followed by a steady decrease following the observation time, having a half-life of 44.11 ± 8.90 min and an AUC-last of 815.05 ± 62.09 min×μg/ml. The distribution of boron in different tissues (heart, liver, lung, stomach, and small intestine) of rats revealed a similar pattern in blood except for that in the brain, kidney, and bladder. In MKN45 cells, boron concentration increased in a time- and concentration-dependent manner. In both CDX and PDX animal models, the boron is preferentially distributed in tumor tissue rather than in blood or normal tissues. In addition, BPA had no significant adverse effects in rats. Taken together, the results suggested that BPA revealed a fast decrease in boron concentration in rats and is more likely to distribute in tumor cells and tissue.
Collapse
Affiliation(s)
- Futian Tang
- Key Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China
- South-East Institute of Lanzhou University, Putian, China
| | - Yujie Wei
- Key Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China
| | - Shining Zhang
- Key Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China
| | - Jianrong Wang
- Key Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China
| | - Wenjiao Gu
- Key Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China
| | - Fenxia Tang
- Key Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China
| | - Xiaohuan Peng
- Key Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China
| | - Yucai Wei
- Key Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China
| | - Jiangyan Liu
- Nuclear Medicine Department, Lanzhou University Second Hospital, Lanzhou, China
| | - Weiqiang Chen
- Key Laboratory of Heavy Ion Radiation Biology and Medicine, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
- School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing, China
- Department of Radiotherapy Technology, Lanhai Nuclear Medicine Research Center, Putian, China
| | - Shixu Zhang
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, China
| | - Long Gu
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, China
- *Correspondence: Yumin Li, ; Long Gu,
| | - Yumin Li
- Key Laboratory of Digestive System Tumor of Gansu Province and Department of Cardiovascular Disease, Lanzhou University Second Hospital, Lanzhou, China
- South-East Institute of Lanzhou University, Putian, China
- *Correspondence: Yumin Li, ; Long Gu,
| |
Collapse
|
24
|
Clinical Viability of Boron Neutron Capture Therapy for Personalized Radiation Treatment. Cancers (Basel) 2022; 14:cancers14122865. [PMID: 35740531 PMCID: PMC9221296 DOI: 10.3390/cancers14122865] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 06/05/2022] [Accepted: 06/08/2022] [Indexed: 12/17/2022] Open
Abstract
Simple Summary Usually, for dose planning in radiotherapy, the tumor is delimited as a volume on the image of the patient together with other clinical considerations based on populational evidence. However, the same prescription dose can provide different results, depending on the patient. Unfortunately, the biological aspects of the tumor are hardly considered in dose planning. Boron Neutron Capture Radiotherapy enables targeted treatment by incorporating boron-10 at the cellular level and irradiating with neutrons of a certain energy so that they produce nuclear reactions locally and almost exclusively damage the tumor cell. This technique is not new, but modern neutron generators and more efficient boron carriers have reactivated the clinical interest of this technique in the pursuit of more precise treatments. In this work, we review the latest technological facilities and future possibilities for the clinical implementation of BNCT and for turning it into a personalized therapy. Abstract Boron Neutron Capture Therapy (BNCT) is a promising binary disease-targeted therapy, as neutrons preferentially kill cells labeled with boron (10B), which makes it a precision medicine treatment modality that provides a therapeutic effect exclusively on patient-specific tumor spread. Contrary to what is usual in radiotherapy, BNCT proposes cell-tailored treatment planning rather than to the tumor mass. The success of BNCT depends mainly on the sufficient spatial biodistribution of 10B located around or within neoplastic cells to produce a high-dose gradient between the tumor and healthy tissue. However, it is not yet possible to precisely determine the concentration of 10B in a specific tissue in real-time using non-invasive methods. Critical issues remain to be resolved if BNCT is to become a valuable, minimally invasive, and efficient treatment. In addition, functional imaging technologies, such as PET, can be applied to determine biological information that can be used for the combined-modality radiotherapy protocol for each specific patient. Regardless, not only imaging methods but also proteomics and gene expression methods will facilitate BNCT becoming a modality of personalized medicine. This work provides an overview of the fundamental principles, recent advances, and future directions of BNCT as cell-targeted cancer therapy for personalized radiation treatment.
Collapse
|
25
|
Wang S, Zhang Z, Miao L, Li Y. Boron Neutron Capture Therapy: Current Status and Challenges. Front Oncol 2022; 12:788770. [PMID: 35433432 PMCID: PMC9009440 DOI: 10.3389/fonc.2022.788770] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2021] [Accepted: 03/04/2022] [Indexed: 11/13/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a re-emerging therapy with the ability to selectively kill tumor cells. After the boron delivery agents enter the tumor tissue and enrich the tumor cells, the thermal neutrons trigger the fission of the boron atoms, leading to the release of boron atoms and then leading to the release of the α particles (4He) and recoil lithium particles (7Li), along with the production of large amounts of energy in the narrow region. With the advantages of targeted therapy and low toxicity, BNCT has become a unique method in the field of radiotherapy. Since the beginning of the last century, BNCT has been emerging worldwide and gradually developed into a technology for the treatment of glioblastoma multiforme, head and neck cancer, malignant melanoma, and other cancers. At present, how to develop and innovate more efficient boron delivery agents and establish a more accurate boron-dose measurement system have become the problem faced by the development of BNCT. We discuss the use of boron delivery agents over the past several decades and the corresponding clinical trials and preclinical outcomes. Furthermore, the discussion brings recommendations on the future of boron delivery agents and this therapy.
Collapse
Affiliation(s)
- Song Wang
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Zhengchao Zhang
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Lele Miao
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Yumin Li
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| |
Collapse
|
26
|
Importance of radiobiological studies for the advancement of boron neutron capture therapy (BNCT). Expert Rev Mol Med 2022; 24:e14. [PMID: 35357286 DOI: 10.1017/erm.2022.7] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Boron neutron capture therapy (BNCT) is a tumour selective particle radiotherapy, based on the administration of boron carriers incorporated preferentially by tumour cells, followed by irradiation with a thermal or epithermal neutron beam. BNCT clinical results to date show therapeutic efficacy, associated with an improvement in patient quality of life and prolonged survival. Translational research in adequate experimental models is necessary to optimise BNCT for different pathologies. This review recapitulates some examples of BNCT radiobiological studies for different pathologies and clinical scenarios, strategies to optimise boron targeting, enhance BNCT therapeutic effect and minimise radiotoxicity. It also describes the radiobiological mechanisms induced by BNCT, and the importance of the detection of biomarkers to monitor and predict the therapeutic efficacy and toxicity of BNCT alone or combined with other strategies. Besides, there is a brief comment on the introduction of accelerator-based neutron sources in BNCT. These sources would expand the clinical BNCT services to more patients, and would help to make BNCT a standard treatment modality for various types of cancer. Radiobiological BNCT studies have been of utmost importance to make progress in BNCT, being essential to design novel, safe and effective clinical BNCT protocols.
Collapse
|
27
|
Key biological mechanisms involved in high-LET radiation therapies with a focus on DNA damage and repair. Expert Rev Mol Med 2022; 24:e15. [PMID: 35357290 DOI: 10.1017/erm.2022.6] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
DNA damage and repair studies are at the core of the radiation biology field and represent also the fundamental principles informing radiation therapy (RT). DNA damage levels are a function of radiation dose, whereas the type of damage and biological effects such as DNA damage complexity, depend on radiation quality that is linear energy transfer (LET). Both levels and types of DNA damage determine cell fate, which can include necrosis, apoptosis, senescence or autophagy. Herein, we present an overview of current RT modalities in the light of DNA damage and repair with emphasis on medium to high-LET radiation. Proton radiation is discussed along with its new adaptation of FLASH RT. RT based on α-particles includes brachytherapy and nuclear-RT, that is proton-boron capture therapy (PBCT) and boron-neutron capture therapy (BNCT). We also discuss carbon ion therapy along with combinatorial immune-based therapies and high-LET RT. For each RT modality, we summarise relevant DNA damage studies. Finally, we provide an update of the role of DNA repair in high-LET RT and we explore the biological responses triggered by differential LET and dose.
Collapse
|
28
|
Takahara K, Miyatake SI, Azuma H, Shiroki R. Boron neutron capture therapy for urological cancers. Int J Urol 2022; 29:610-616. [PMID: 35240726 DOI: 10.1111/iju.14855] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Accepted: 02/21/2022] [Indexed: 01/18/2023]
Abstract
Boron neutron capture therapy is based on a nuclear reaction between the nonradioactive isotope boron-10 and either low-energy thermal neutrons or high-energy epithermal neutrons, which generate high linear energy transfer α particles and a recoiled lithium nucleus (7 Li) that selectively destroys the DNA helix in tumor cells. Boron neutron capture therapy is an emerging procedure aimed at improving the therapeutic ratio for the traditional treatment of various malignancies, which has been studied clinically in a variety of diseases, including glioblastoma, head and neck cancer, cutaneous melanoma, hepatocellular carcinoma, lung cancer, and extramammary Paget's disease. However, boron neutron capture therapy has not been clinically performed for urological cancers, excluding genital extramammary Paget's disease that appeared at the scrotum to penis area. In this review, we aimed to provide an updated summary of the current clinical literature of patients treated with boron neutron capture therapy and to focus on the future prospects of boron neutron capture therapy for urological cancers.
Collapse
Affiliation(s)
- Kiyoshi Takahara
- Department of Urology, School of Medicine, Fujita Health University, Aichi, Japan
| | - Shin-Ichi Miyatake
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.,Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| | - Haruhito Azuma
- Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Ryoichi Shiroki
- Department of Urology, School of Medicine, Fujita Health University, Aichi, Japan
| |
Collapse
|
29
|
Porra L, Seppälä T, Wendland L, Revitzer H, Joensuu H, Eide P, Koivunoro H, Smick N, Smick T, Tenhunen M. Accelerator-based boron neutron capture therapy facility at the Helsinki University Hospital. Acta Oncol 2022; 61:269-273. [PMID: 34569418 DOI: 10.1080/0284186x.2021.1979646] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Liisa Porra
- Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Tiina Seppälä
- Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Lauri Wendland
- Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Hannu Revitzer
- Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Heikki Joensuu
- Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Paul Eide
- Neutron Therapeutics Inc., Danvers, MA, USA
| | | | - Noah Smick
- Neutron Therapeutics Inc., Danvers, MA, USA
| | | | - Mikko Tenhunen
- Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| |
Collapse
|
30
|
Kanygin V, Kichigin A, Zaboronok A, Kasatova A, Petrova E, Tsygankova A, Zavjalov E, Mathis BJ, Taskaev S. In Vivo Accelerator-Based Boron Neutron Capture Therapy for Spontaneous Tumors in Large Animals: Case Series. BIOLOGY 2022; 11:138. [PMID: 35053138 PMCID: PMC8773183 DOI: 10.3390/biology11010138] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 01/12/2022] [Accepted: 01/12/2022] [Indexed: 11/29/2022]
Abstract
(1) Background: accelerator-based neutron sources are a new frontier for BNCT but many technical issues remain. We aimed to study such issues and results in larger-animal BNCT (cats and dogs) with naturally occurring, malignant tumors in different locations as an intermediate step in translating current research into clinical practice. (2) Methods: 10 pet cats and dogs with incurable, malignant tumors that had no treatment alternatives were included in this study. A tandem accelerator with vacuum insulation was used as a neutron source. As a boron-containing agent, 10B-enriched sodium borocaptate (BSH) was used at a dose of 100 mg/kg. Animal condition as well as tumor progression/regression were monitored. (3) Results: regression of tumors in response to treatment, improvements in the overall clinical picture, and an increase in the estimated duration and quality of life were observed. Treatment-related toxicity was mild and reversible. (4) Conclusions: our study contributes to preparations for human BNCT clinical trials and suggests utility for veterinary oncology.
Collapse
Affiliation(s)
- Vladimir Kanygin
- Laboratory of Medical and Biological Problems of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Str., 630090 Novosibirsk, Russia; (V.K.); (A.K.); (A.T.); (E.Z.)
| | - Aleksandr Kichigin
- Laboratory of Medical and Biological Problems of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Str., 630090 Novosibirsk, Russia; (V.K.); (A.K.); (A.T.); (E.Z.)
| | - Alexander Zaboronok
- Laboratory of Medical and Biological Problems of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Str., 630090 Novosibirsk, Russia; (V.K.); (A.K.); (A.T.); (E.Z.)
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Ibaraki, Japan
| | - Anna Kasatova
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, 11, Acad. Lavrentieva Ave., 630090 Novosibirsk, Russia; (A.K.); (S.T.)
| | - Elena Petrova
- Veterinary Clinic “Best”, 57 Frunze Str., 630005 Novosibirsk, Russia;
| | - Alphiya Tsygankova
- Laboratory of Medical and Biological Problems of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Str., 630090 Novosibirsk, Russia; (V.K.); (A.K.); (A.T.); (E.Z.)
- Nikolaev Institute of Inorganic Chemistry SB RAS, 3, Acad. Lavrentieva Ave., 630090 Novosibirsk, Russia
| | - Evgenii Zavjalov
- Laboratory of Medical and Biological Problems of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Str., 630090 Novosibirsk, Russia; (V.K.); (A.K.); (A.T.); (E.Z.)
- Center for Genetic Resources of Laboratory Animals, Institute of Cytology and Genetics SB RAS, 10, Acad. Lavrentieva Ave., 630090 Novosibirsk, Russia
| | - Bryan J. Mathis
- International Medical Center, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba 305-8576, Ibaraki, Japan;
| | - Sergey Taskaev
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, 11, Acad. Lavrentieva Ave., 630090 Novosibirsk, Russia; (A.K.); (S.T.)
- Laboratory of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Str., 630090 Novosibirsk, Russia
| |
Collapse
|
31
|
Ciardiello A, Altierix S, Ballarini F, Bocci V, Bortolussi S, Cansolino L, Carlotti D, Ciocca M, Faccini R, Facoetti A, Ferrari C, Ficcadenti L, Furfaro E, Giagu S, Iacoangeli F, Macioce G, Mancini-Terracciano C, Messina A, Milazzo L, Pacifico S, Piccolella S, Postuma I, Rotili D, Vercesi V, Voena C, Vulcano F, Capuani S. Multimodal evaluation of 19F-BPA internalization in pancreatic cancer cells for boron capture and proton therapy potential applications. Phys Med 2022; 94:75-84. [PMID: 34999515 DOI: 10.1016/j.ejmp.2021.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 11/12/2021] [Accepted: 12/19/2021] [Indexed: 10/19/2022] Open
Abstract
PURPOSE One of the obstacles to the application of Boron Neutron Capture Therapy (BNCT) and Proton Boron Fusion Therapy (PBFT) concerns the measurement of borated carriers' biodistribution. The objective of the present study was to evaluate the in vitro internalization of the 19F-labelled p-boronophenylalanine (19F-BPA) in the human cancer pancreatic cell line (PANC-1) for the potential application of BNCT and PBFT in pancreatic cancer. The 19F-BPA carrier has the advantage that its bio-distribution may be monitored in vivo using 19F-Nuclear Magnetic Resonance (19F NMR). MATERIALS AND METHODS The 19F-BPA internalization in PANC-1 cells was evaluated using three independent techniques on cellular samples left in contact with growing medium enriched with 13.6 mM 19F-BPA corresponding to a 11B concentration of 120 ppm: neutron autoradiography, which quantifies boron; liquid chromatography hyphenated to tandem mass spectrometry and UV-Diode Array Detection (UV-DAD), which quantifies 19F-BPA molecule; and 19F NMR spectroscopy, which detects fluorine nuclei. RESULTS Our studies suggested that 19F-BPA is internalized by PANC-1 cells. The three methods provided consistent results of about 50% internalization fraction at 120 ppm of 11B. Small variations (less than 15%) in internalization fraction are mainly dependent on the proliferation state of the cells. CONCLUSIONS The ability of 19F NMR spectroscopy to study 19F-BPA internalization was validated by well-established independent techniques. The multimodal approach we used suggests 19F-BPA as a promising BNCT/PBFT carrier for the treatment of pancreatic cancer. Since the quantification is performed at doses useful for BNCT/PBFT, 19F NMR can be envisaged to monitor 19F-BPA bio-distribution during the therapy.
Collapse
Affiliation(s)
- Andrea Ciardiello
- Sapienza University, Physics Department, pl.e Aldo Moro 2, 00185 Rome, Italy; INFN, Sezione di Roma, pl.e Aldo Moro 2, 00185 Rome, Italy
| | - Saverio Altierix
- Pavia University, Physics Department, via A. Bassi 6, 27100 Pavia, Italy; INFN, Sezione di Pavia, via A. Bassi 6, 27100 Pavia, Italy
| | - Francesca Ballarini
- Pavia University, Physics Department, via A. Bassi 6, 27100 Pavia, Italy; INFN, Sezione di Pavia, via A. Bassi 6, 27100 Pavia, Italy
| | - Valerio Bocci
- INFN, Sezione di Roma, pl.e Aldo Moro 2, 00185 Rome, Italy
| | - Silva Bortolussi
- Pavia University, Physics Department, via A. Bassi 6, 27100 Pavia, Italy; INFN, Sezione di Pavia, via A. Bassi 6, 27100 Pavia, Italy
| | - Laura Cansolino
- INFN, Sezione di Pavia, via A. Bassi 6, 27100 Pavia, Italy; Pavia University, Laboratory of Experimental Surgery, Clinical, Surgical, Diagnostic, Pediatric Science Department, via Ferrata, 27100 Pavia, Italy
| | - Daniele Carlotti
- INFN, Sezione di Roma, pl.e Aldo Moro 2, 00185 Rome, Italy; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
| | - Mario Ciocca
- INFN, Sezione di Pavia, via A. Bassi 6, 27100 Pavia, Italy; National Center of Oncological Hadrontherapy, CNAO, via Campeggi 53, 27100 Pavia, Italy
| | - Riccardo Faccini
- Sapienza University, Physics Department, pl.e Aldo Moro 2, 00185 Rome, Italy; INFN, Sezione di Roma, pl.e Aldo Moro 2, 00185 Rome, Italy
| | - Angelica Facoetti
- INFN, Sezione di Pavia, via A. Bassi 6, 27100 Pavia, Italy; National Center of Oncological Hadrontherapy, CNAO, via Campeggi 53, 27100 Pavia, Italy
| | - Cinzia Ferrari
- INFN, Sezione di Pavia, via A. Bassi 6, 27100 Pavia, Italy; Pavia University, Laboratory of Experimental Surgery, Clinical, Surgical, Diagnostic, Pediatric Science Department, via Ferrata, 27100 Pavia, Italy
| | | | - Emiliano Furfaro
- Sapienza University, Physics Department, pl.e Aldo Moro 2, 00185 Rome, Italy
| | - Stefano Giagu
- Sapienza University, Physics Department, pl.e Aldo Moro 2, 00185 Rome, Italy; INFN, Sezione di Roma, pl.e Aldo Moro 2, 00185 Rome, Italy
| | | | - Giampiero Macioce
- Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
| | - Carlo Mancini-Terracciano
- Sapienza University, Physics Department, pl.e Aldo Moro 2, 00185 Rome, Italy; INFN, Sezione di Roma, pl.e Aldo Moro 2, 00185 Rome, Italy
| | - Andrea Messina
- Sapienza University, Physics Department, pl.e Aldo Moro 2, 00185 Rome, Italy; INFN, Sezione di Roma, pl.e Aldo Moro 2, 00185 Rome, Italy
| | - Luisa Milazzo
- Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
| | - Severina Pacifico
- University of Campania "Luigi Vanvitelli", Environmental, Biological and Pharmaceutical Sciences and Technologies Department, Via Vivaldi 43, 81100 Caserta, Italy; INFN, Sezione di Napoli, Strada Comunale Cinthia, 80126 Napoli, (Italy)
| | - Simona Piccolella
- University of Campania "Luigi Vanvitelli", Environmental, Biological and Pharmaceutical Sciences and Technologies Department, Via Vivaldi 43, 81100 Caserta, Italy; INFN, Sezione di Napoli, Strada Comunale Cinthia, 80126 Napoli, (Italy)
| | - Ian Postuma
- INFN, Sezione di Pavia, via A. Bassi 6, 27100 Pavia, Italy
| | - Dante Rotili
- Sapienza University, Department of Chemistry and Technologies of Drugs, P.le A. Moro 2, 00185 Rome, Italy
| | | | - Cecilia Voena
- INFN, Sezione di Roma, pl.e Aldo Moro 2, 00185 Rome, Italy.
| | - Francesca Vulcano
- Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
| | - Silvia Capuani
- INFN, Sezione di Roma, pl.e Aldo Moro 2, 00185 Rome, Italy; CNR ISC c/o Sapienza University Physics Department, P.le A.Moro 2, 00185 Rome, Italy; Centro Fermi - Museo Storico Della Fisica e Centro Studi e Ricerche Enrico Fermi, Piazza del Viminale 1, Rome 00184, Italy
| |
Collapse
|
32
|
Nuez-Martinez M, Pinto CIG, Guerreiro JF, Mendes F, Marques F, Muñoz-Juan A, Xavier JAM, Laromaine A, Bitonto V, Protti N, Crich SG, Teixidor F, Viñas C. Cobaltabis(dicarbollide) ([ o-COSAN] -) as Multifunctional Chemotherapeutics: A Prospective Application in Boron Neutron Capture Therapy (BNCT) for Glioblastoma. Cancers (Basel) 2021; 13:6367. [PMID: 34944987 PMCID: PMC8699431 DOI: 10.3390/cancers13246367] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 12/10/2021] [Accepted: 12/16/2021] [Indexed: 12/12/2022] Open
Abstract
PURPOSE The aim of our study was to assess if the sodium salt of cobaltabis(dicarbollide) and its di-iodinated derivative (Na[o-COSAN] and Na[8,8'-I2-o-COSAN]) could be promising agents for dual anti-cancer treatment (chemotherapy + BNCT) for GBM. METHODS The biological activities of the small molecules were evaluated in vitro with glioblastoma cells lines U87 and T98G in 2D and 3D cell models and in vivo in the small model animal Caenorhabditis elegans (C. elegans) at the L4-stage and using the eggs. RESULTS Our studies indicated that only spheroids from the U87 cell line have impaired growth after treatment with both compounds, suggesting an increased resistance from T98G spheroids, contrary to what was observed in the monolayer culture, which highlights the need to employ 3D models for future GBM studies. In vitro tests in U87 and T98G cells conclude that the amount of 10B inside the cells is enough for BNCT irradiation. BNCT becomes more effective on T98G after their incubation with Na[8,8'-I2-o-COSAN], whereas no apparent cell-killing effect was observed for untreated cells. CONCLUSIONS These small molecules, particularly [8,8'-I2-o-COSAN]-, are serious candidates for BNCT now that the facilities of accelerator-based neutron sources are more accessible, providing an alternative treatment for resistant glioblastoma.
Collapse
Affiliation(s)
- Miquel Nuez-Martinez
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193 Bellaterra, Spain; (M.N.-M.); (A.M.-J.); (J.A.M.X.); (A.L.); (F.T.)
| | - Catarina I. G. Pinto
- Centro de Ciências e Tecnologias Nucleares, Departamento de Engenharia e Ciências Nucleares, Instituto Superior Técnico, Universidade de Lisboa, 2695-066 Bobadela, Portugal; (C.I.G.P.); (J.F.G.); (F.M.); (F.M.)
| | - Joana F. Guerreiro
- Centro de Ciências e Tecnologias Nucleares, Departamento de Engenharia e Ciências Nucleares, Instituto Superior Técnico, Universidade de Lisboa, 2695-066 Bobadela, Portugal; (C.I.G.P.); (J.F.G.); (F.M.); (F.M.)
| | - Filipa Mendes
- Centro de Ciências e Tecnologias Nucleares, Departamento de Engenharia e Ciências Nucleares, Instituto Superior Técnico, Universidade de Lisboa, 2695-066 Bobadela, Portugal; (C.I.G.P.); (J.F.G.); (F.M.); (F.M.)
| | - Fernanda Marques
- Centro de Ciências e Tecnologias Nucleares, Departamento de Engenharia e Ciências Nucleares, Instituto Superior Técnico, Universidade de Lisboa, 2695-066 Bobadela, Portugal; (C.I.G.P.); (J.F.G.); (F.M.); (F.M.)
| | - Amanda Muñoz-Juan
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193 Bellaterra, Spain; (M.N.-M.); (A.M.-J.); (J.A.M.X.); (A.L.); (F.T.)
| | - Jewel Ann Maria Xavier
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193 Bellaterra, Spain; (M.N.-M.); (A.M.-J.); (J.A.M.X.); (A.L.); (F.T.)
| | - Anna Laromaine
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193 Bellaterra, Spain; (M.N.-M.); (A.M.-J.); (J.A.M.X.); (A.L.); (F.T.)
| | - Valeria Bitonto
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy; (V.B.); (S.G.C.)
| | | | - Simonetta Geninatti Crich
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy; (V.B.); (S.G.C.)
| | - Francesc Teixidor
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193 Bellaterra, Spain; (M.N.-M.); (A.M.-J.); (J.A.M.X.); (A.L.); (F.T.)
| | - Clara Viñas
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193 Bellaterra, Spain; (M.N.-M.); (A.M.-J.); (J.A.M.X.); (A.L.); (F.T.)
| |
Collapse
|
33
|
Xu J, Wang J, Wei Q. Boron neutron capture therapy in clinical application:Progress and prospect. CHINESE SCIENCE BULLETIN-CHINESE 2021. [DOI: 10.1360/tb-2021-0907] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
34
|
Trivillin VA, Langle YV, Palmieri MA, Pozzi ECC, Thorp SI, Benitez Frydryk DN, Garabalino MA, Monti Hughes A, Curotto PM, Colombo LL, Santa Cruz IS, Ramos PS, Itoiz ME, Argüelles C, Eiján AM, Schwint AE. Evaluation of local, regional and abscopal effects of Boron Neutron Capture Therapy (BNCT) combined with immunotherapy in an ectopic colon cancer model. Br J Radiol 2021; 94:20210593. [PMID: 34520668 DOI: 10.1259/bjr.20210593] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
OBJECTIVE The aim of the present study was to evaluate the local and regional therapeutic efficacy and abscopal effect of BNCT mediated by boronophenyl-alanine, combined with Bacillus Calmette-Guerin (BCG) as an immunotherapy agent in this model. METHODS The local effect of treatment was evaluated in terms of tumor response in the irradiated tumor-bearing right hind flank. Metastatic spread to tumor-draining lymph nodes was analyzed as an indicator of regional effect. The abscopal effect of treatment was assessed as tumor growth inhibition in the contralateral (non-irradiated) left hind flank inoculated with tumor cells 2 weeks post-irradiation. The experimental groups BNCT, BNCT + BCG, BCG, Beam only (BO), BO +BCG, SHAM (tumor-bearing, no treatment, same manipulation) were studied. RESULTS BNCT and BNCT + BCG induced a highly significant local anti-tumor response, whereas BCG alone induced a weak local effect. BCG and BNCT + BCG induced a significant abscopal effect in the contralateral non-irradiated leg. The BNCT + BCG group showed significantly less metastatic spread to tumor-draining lymph nodes vs SHAM and vs BO. CONCLUSION This study suggests that BNCT + BCG-immunotherapy would induce local, regional and abscopal effects in tumor-bearing animals. BNCT would be the main effector of the local anti-tumor effect whereas BCG would be the main effector of the abscopal effect. ADVANCES IN KNOWLEDGE Although the local effect of BNCT has been widely evidenced, this is the first study to show the local, regional and abscopal effects of BNCT combined with immunotherapy, contributing to comprehensive cancer treatment with combined therapies.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Yanina V Langle
- Universidad de Buenos Aires, Instituto de Oncología Ángel H. Roffo, Área Investigación, Buenos Aires, Argentina
| | - Mónica A Palmieri
- Departamento de Biodiversidad y Biología Experimental, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina
| | | | - Silvia I Thorp
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | | | | | - Andrea Monti Hughes
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Paula M Curotto
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Lucas L Colombo
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.,Universidad de Buenos Aires, Instituto de Oncología Ángel H. Roffo, Área Investigación, Buenos Aires, Argentina
| | - Iara S Santa Cruz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Paula S Ramos
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - María E Itoiz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina.,Facultad de Odontología, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina
| | - Claudia Argüelles
- Instituto Nacional de Producción de Biológicos, ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina
| | - Ana M Eiján
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.,Universidad de Buenos Aires, Instituto de Oncología Ángel H. Roffo, Área Investigación, Buenos Aires, Argentina
| | - Amanda E Schwint
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| |
Collapse
|
35
|
Development of an Imaging Technique for Boron Neutron Capture Therapy. Cells 2021; 10:cells10082135. [PMID: 34440904 PMCID: PMC8392566 DOI: 10.3390/cells10082135] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Revised: 08/17/2021] [Accepted: 08/17/2021] [Indexed: 12/02/2022] Open
Abstract
The development of 4-10B-borono-2-18F-fluoro-L-phenylalanine (18FBPA) for use in positron emission tomography (PET) has contributed to the progress of boron neutron capture therapy (BNCT). 18FBPA has shown similar pharmacokinetics and distribution to 4-10B-borono-L-phenylalanine (BPA) under various conditions in many animal studies. 18FBPA PET is useful for treatment indication. A higher 18FBPA accumulation ratio of the tumor to the surrounding normal tissue (T/N ratio) indicates that a superior treatment effect is expected. In clinical settings, a T/N ratio of higher than 2.5 or 3 is often used for patient selection. Moreover, 18FBPA PET is useful for predicting the 10B concentration delivered to the tumor and surrounding normal tissues, enabling high-precision treatment planning. Precise dose prediction using 18FBPA PET data has greatly improved the treatment accuracy of BNCT. However, the methodology used for the data analysis of 18FBPA PET findings varies; thus, data should be evaluated using a consistent methodology so as to be more reliable. In addition to PET applications, the development of 18FBPA as a contrast agent for magnetic resonance imaging that combines gadolinium and 10B is also in progress.
Collapse
|
36
|
Chan WJ, Cho HL, Goudar V, Bupphathong S, Shu CH, Kung C, Tseng FG. Boron-enriched polyvinyl-alcohol/boric-acid nanoparticles for boron neutron capture therapy. Nanomedicine (Lond) 2021; 16:441-452. [DOI: 10.2217/nnm-2020-0401] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background: Due to the noninvasive nature of boron neutron capture therapy (BNCT), it is considered a promising cancer treatment method. Aim: To investigate whether polyvinyl alcohol/boric acid crosslinked nanoparticles (PVA/BA NPs) are an efficient delivery system for BNCT. Materials & methods: PVA/BA NPs were synthesized and cocultured with brain and oral cancers cells for BNCT. Results: PVA/BA NPs had a boron-loading capacity of 7.83 ± 1.75 w/w%. They accumulated in brain and oral cancers cells at least threefold more than in fibroblasts and macrophages. The IC50 values of the brain and oral cancers cells were at least ninefold and sixfold lower than those of fibroblasts and macrophages, respectively. Conclusion: Theoretically, PVA/BA NPs target brain and oral cancers cells and could offer improved therapeutic outcomes of BNCT.
Collapse
Affiliation(s)
- Wei-Jen Chan
- Department of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Han-Lin Cho
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Venkanagouda Goudar
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Sasinan Bupphathong
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Chi-Hung Shu
- Department of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Chi Kung
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Fan-Gang Tseng
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
- Frontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan
- Research Center for Applied Sciences, Academia Sinica, Taipei 11529, Taiwan
| |
Collapse
|
37
|
Torresan V, Guadagnini A, Badocco D, Pastore P, Muñoz Medina GA, Fernàndez van Raap MB, Postuma I, Bortolussi S, Bekić M, Čolić M, Gerosa M, Busato A, Marzola P, Amendola V. Biocompatible Iron-Boron Nanoparticles Designed for Neutron Capture Therapy Guided by Magnetic Resonance Imaging. Adv Healthc Mater 2021; 10:e2001632. [PMID: 33369251 DOI: 10.1002/adhm.202001632] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2020] [Revised: 11/04/2020] [Indexed: 12/13/2022]
Abstract
The combination of multiple functions in a single nanoparticle (NP) represents a key advantage of nanomedicine compared to traditional medical approaches. This is well represented by radiotherapy in which the dose of ionizing radiation should be calibrated on sensitizers biodistribution. Ideally, this is possible when the drug acts both as radiation enhancer and imaging contrast agent. Here, an easy, one-step, laser-assisted synthetic procedure is used to generate iron-boron (Fe-B) NPs featuring the set of functions required to assist neutron capture therapy (NCT) with magnetic resonance imaging. The Fe-B NPs exceed by three orders of magnitude the payload of boron isotopes contained in clinical sensitizers. The Fe-B NPs have magnetic properties of interest also for magnetophoretic accumulation in tissues and magnetic hyperthermia to assist drug permeation in tissues. Besides, Fe-B NPs are biocompatible and undergo slow degradation in the lysosomal environment that facilitates in vivo clearance through the liver-spleen-kidneys pathway. Overall, the Fe-B NPs represent a new promising tool for future exploitation in magnetic resonance imaging-guided boron NCT at higher levels of efficacy and tolerability.
Collapse
Affiliation(s)
- Veronica Torresan
- Department of Chemical Sciences University of Padova Via Marzolo 1 Padova I‐35131 Italy
| | - Andrea Guadagnini
- Department of Chemical Sciences University of Padova Via Marzolo 1 Padova I‐35131 Italy
| | - Denis Badocco
- Department of Chemical Sciences University of Padova Via Marzolo 1 Padova I‐35131 Italy
| | - Paolo Pastore
- Department of Chemical Sciences University of Padova Via Marzolo 1 Padova I‐35131 Italy
| | - Guillermo Arturo Muñoz Medina
- Physics Institute of La Plata (IFLP‐CONICET) Physics Department, Faculty of Exact Sciences National University of La Plata La Plata 1900 Argentina
| | - Marcela B. Fernàndez van Raap
- Physics Institute of La Plata (IFLP‐CONICET) Physics Department, Faculty of Exact Sciences National University of La Plata La Plata 1900 Argentina
| | - Ian Postuma
- INFN (National Institute of Nuclear Physics) Pavia Via Bassi 6 Pavia 27100 Italy
| | - Silva Bortolussi
- INFN (National Institute of Nuclear Physics) Pavia Via Bassi 6 Pavia 27100 Italy
- Department of Physics University of Pavia Pavia 27100 Italy
| | - Marina Bekić
- Institute for the Application of Nuclear Energy University of Belgrade Belgrade 11080 Serbia
| | - Miodrag Čolić
- Institute for the Application of Nuclear Energy University of Belgrade Belgrade 11080 Serbia
- Medical Faculty Foča University of East Sarajevo Republika Srpska Foča 73300 Bosnia and Herzegovina
| | - Marco Gerosa
- Department of Computer Science University of Verona Verona 37134 Italy
| | - Alice Busato
- Department of Computer Science University of Verona Verona 37134 Italy
| | - Pasquina Marzola
- Department of Computer Science University of Verona Verona 37134 Italy
| | - Vincenzo Amendola
- Department of Chemical Sciences University of Padova Via Marzolo 1 Padova I‐35131 Italy
| |
Collapse
|
38
|
Malouff TD, Seneviratne DS, Ebner DK, Stross WC, Waddle MR, Trifiletti DM, Krishnan S. Boron Neutron Capture Therapy: A Review of Clinical Applications. Front Oncol 2021; 11:601820. [PMID: 33718149 PMCID: PMC7952987 DOI: 10.3389/fonc.2021.601820] [Citation(s) in RCA: 91] [Impact Index Per Article: 30.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Accepted: 01/27/2021] [Indexed: 01/22/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is an emerging treatment modality aimed at improving the therapeutic ratio for traditionally difficult to treat tumors. BNCT utilizes boronated agents to preferentially deliver boron-10 to tumors, which, after undergoing irradiation with neutrons, yields litihium-7 and an alpha particle. The alpha particle has a short range, therefore preferentially affecting tumor tissues while sparing more distal normal tissues. To date, BNCT has been studied clinically in a variety of disease sites, including glioblastoma multiforme, meningioma, head and neck cancers, lung cancers, breast cancers, hepatocellular carcinoma, sarcomas, cutaneous malignancies, extramammary Paget's disease, recurrent cancers, pediatric cancers, and metastatic disease. We aim to provide an up-to-date and comprehensive review of the studies of each of these disease sites, as well as a review on the challenges facing adoption of BNCT.
Collapse
Affiliation(s)
- Timothy D Malouff
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States
| | | | - Daniel K Ebner
- Warren Alpert Medical School, Brown University, Providence, RI, United States
| | - William C Stross
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States
| | - Mark R Waddle
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States
| | - Daniel M Trifiletti
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States
| | - Sunil Krishnan
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States
| |
Collapse
|
39
|
Pharmacokinetics of 10B-p-boronophenylalanine (BPA) in the blood and tumors in human patients: A critical review with special reference to tumor-to-blood (T/B) ratios using resected tumor samples. Appl Radiat Isot 2020; 166:109308. [PMID: 32823081 DOI: 10.1016/j.apradiso.2020.109308] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 06/19/2020] [Accepted: 06/22/2020] [Indexed: 11/23/2022]
Abstract
We reviewed 10B concentration kinetics in the blood and tumors in human patients administered with BPA. The 10B concentration in the blood peaked at the end of intravenous infusion of BPA, followed by a biphasic-decreasing curve with half-lives for the first and second components of the curve being 0.7-3.7 and 7.2-12.0 h, respectively. The mean tumor-to-blood (T/B) ratio obtained from resected tumor samples was 3.40 ± 0.83 for melanoma and the ratio ranged from 1.4 to 4.7 for glioblastoma.
Collapse
|
40
|
Schwint AE, Monti Hughes A, Garabalino MA, Santa Cruz GA, González SJ, Longhino J, Provenzano L, Oña P, Rao M, Cantarelli MDLÁ, Leiras A, Olivera MS, Trivillin VA, Alessandrini P, Brollo F, Boggio E, Costa H, Ventimiglia R, Binia S, Pozzi ECC, Nievas SI, Santa Cruz IS. Clinical Veterinary Boron Neutron Capture Therapy (BNCT) Studies in Dogs with Head and Neck Cancer: Bridging the Gap between Translational and Clinical Studies. BIOLOGY 2020; 9:biology9100327. [PMID: 33036386 PMCID: PMC7599538 DOI: 10.3390/biology9100327] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 10/01/2020] [Accepted: 10/05/2020] [Indexed: 01/08/2023]
Abstract
Simple Summary Boron Neutron Capture Therapy (BNCT) is a treatment for cancer based on the selective accumulation in tumor of boron compounds, followed by external irradiation with neutrons. The interaction between boron-10 and a neutron gives rise to very energetic particles that travel only a very short distance (approximately the diameter of a cell) and are lethal for the cell. In this way, BNCT damages tumor tissue selectively while preserving normal tissue. BNCT has proved effective to treat certain tumors in clinical trials worldwide, with room for improvement. Our group has worked on animal models to improve the efficacy of BNCT, in particular for head and neck cancer. Herein we performed clinical veterinary BNCT studies in five terminal dog patients with head and neck cancer with no other therapeutic option. In all cases we observed partial tumor response, clinical benefit, and extension of estimated survival time at recruitment with excellent quality of life. Toxicity associated to the treatment was mild/moderate and reversible. These studies contribute towards preparation for clinical BNCT trials for head and neck cancer in Argentina and suggest a potential role for BNCT in veterinary medicine. Abstract Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have shown the therapeutic efficacy of BNCT for head and neck cancer. The present BNCT studies in veterinary patients with head and neck cancer were performed to optimize the therapeutic efficacy of BNCT, contribute towards exploring the role of BNCT in veterinary medicine, put in place technical aspects for an upcoming clinical trial of BNCT for head and neck cancer at the RA-6 Nuclear Reactor, and assess the feasibility of employing the existing B2 beam to treat large, deep-seated tumors. Five dogs with head and neck cancer with no other therapeutic option were treated with two applications of BNCT mediated by boronophenyl-alanine (BPA) separated by 3–5 weeks. Two to three portals per BNCT application were used to achieve a potentially therapeutic dose over the tumor without exceeding normal tissue tolerance. Clinical and Computed Tomography results evidenced partial tumor control in all cases, with slight-moderate mucositis, excellent life quality, and prolongation in the survival time estimated at recruitment. These exploratory studies show the potential value of BNCT in veterinary medicine and contribute towards initiating a clinical BNCT trial for head and neck cancer at the RA-6 clinical facility.
Collapse
Affiliation(s)
- Amanda E. Schwint
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
- Correspondence: ; Tel.: +54-911-6496-7168
| | - Andrea Monti Hughes
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Marcela A. Garabalino
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Gustavo A. Santa Cruz
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Sara J. González
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Juan Longhino
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Lucas Provenzano
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Paulina Oña
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Monica Rao
- Hospital Veterinario, Gobernador M. Ugarte 2152, Olivos, B1636BWT, Provincia Buenos Aires, Argentina;
| | | | - Andrea Leiras
- Independent Veterinarian, Huilqui 12356, San Carlos de Bariloche, 8400, Provincia Rio Negro, Argentina;
| | - María Silvina Olivera
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Verónica A. Trivillin
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Paula Alessandrini
- Independent Veterinarian, Lonquimay 3817, San Carlos de Bariloche, 8400, Provincia Rio Negro, Argentina;
| | - Fabricio Brollo
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Esteban Boggio
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Hernan Costa
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Romina Ventimiglia
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Sergio Binia
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Emiliano C. C. Pozzi
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Susana I. Nievas
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Iara S. Santa Cruz
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| |
Collapse
|
41
|
Santa Cruz IS, Garabalino MA, Trivillin VA, Itoiz ME, Pozzi ECC, Thorp S, Curotto P, Guidobono JS, Heber EM, Nigg DW, Schwint AE, Monti Hughes A. Optimization of the classical oral cancerization protocol in hamster to study oral cancer therapy. Oral Dis 2020; 26:1175-1184. [PMID: 32297432 DOI: 10.1111/odi.13358] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 04/01/2020] [Accepted: 04/03/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVE(S) The hamster carcinogenesis model recapitulates oral oncogenesis. Dimethylbenz[a]anthracene (DMBA) cancerization induces early severe mucositis, affecting animal's welfare and causing tissue loss and pouch shortening. "Short" pouches cannot be everted for local irradiation for boron neutron capture therapy (BNCT). Our aim was to optimize the DMBA classical cancerization protocol to avoid severe mucositis, without affecting tumor development. We evaluated BNCT in animals cancerized with this novel protocol. MATERIALS AND METHODS We studied: Classical cancerization protocol (24 applications) and Classical with two interruptions (completed at the end of the cancerization protocol). BNCT mediated by boronophenylalanine (BPA) was performed in both groups. RESULTS The twice-interrupted group exhibited a significantly lower percentage of animals with severe mucositis versus the non-interrupted group (17% versus 71%) and a significantly higher incidence of long pouches (100% versus 53%). Tumor development and the histologic characteristics of tumor and precancerous tissue were not affected by the interruptions. For both groups, overall tumor response was more than 80%, with a similar incidence of BNCT-induced severe mucositis. CONCLUSION(S) The twice-interrupted protocol reduced severe mucositis during cancerization without affecting tumor development. This favored the animal's welfare and reduced the number of animals to be cancerized for our studies, without affecting BNCT response.
Collapse
Affiliation(s)
- Iara S Santa Cruz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | | | - Verónica A Trivillin
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - María E Itoiz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Facultad de Odontología, UBA, Buenos Aires, Argentina
| | | | - Silvia Thorp
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Paula Curotto
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Juan S Guidobono
- Instituto de Ecología, Genética y Evolución de Buenos Aires (IEGEBA), CONICET, UBA, Buenos Aires, Argentina
| | - Elisa M Heber
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - David W Nigg
- Idaho National Laboratory USA, Idaho Falls, ID, USA
| | - Amanda E Schwint
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| |
Collapse
|
42
|
Dymova MA, Taskaev SY, Richter VA, Kuligina EV. Boron neutron capture therapy: Current status and future perspectives. Cancer Commun (Lond) 2020; 40:406-421. [PMID: 32805063 PMCID: PMC7494062 DOI: 10.1002/cac2.12089] [Citation(s) in RCA: 108] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 06/09/2020] [Accepted: 08/09/2020] [Indexed: 12/11/2022] Open
Abstract
The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new, more specific boron delivery agents.
Collapse
Affiliation(s)
- Mayya Alexandrovna Dymova
- Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 8, Novosibirsk, 630090, Russia
| | - Sergey Yurjevich Taskaev
- Budker Institute of Nuclear Physics, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 11, Novosibirsk, 630090, Russia.,Laboratory of Boron Neutron Capture Therapy, Novosibirsk State University, Pirogova str. 1, Novosibirsk, 630090, Russia
| | - Vladimir Alexandrovich Richter
- Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 8, Novosibirsk, 630090, Russia
| | - Elena Vladimirovna Kuligina
- Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 8, Novosibirsk, 630090, Russia
| |
Collapse
|
43
|
Jiang SH, Hsueh Liu YW, Chou FI, Liu HM, Peir JJ, Liu YH, Huang YS, Wang LW, Chen YW, Yen SH, Wu YH, Liu CS, Lee JC, Chang CW, Wang SJ, Huang WS, Kai JJ. The overview and prospects of BNCT facility at Tsing Hua Open-pool reactor. Appl Radiat Isot 2020; 161:109143. [DOI: 10.1016/j.apradiso.2020.109143] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 01/17/2020] [Accepted: 03/20/2020] [Indexed: 11/17/2022]
|
44
|
Saini G, Shukla R, Sood KS, Shukla SK, Chandra R. Role of Proton Beam Therapy in Current Day Radiation Oncology Practice. ASIAN JOURNAL OF ONCOLOGY 2020. [DOI: 10.1055/s-0040-1713703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
AbstractProton beam therapy (PBT), because of its unique physics of no–exit dose deposition in the tissue, is an exciting prospect. The phenomenon of Bragg peak allows protons to deposit their almost entire energy towards the end of the path of the proton and stops any further dose delivery. Braggs peak equips PBT with superior dosimetric advantage over photons or electrons because PBT doesn’t traverse the target/body but is stopped sharply at an energy dependent depth in the target/body. It also has no exit dose. Because of no exit dose and normal tissue sparing, PBT is hailed for its potential to bring superior outcomes. Pediatric malignancies is the most common malignancy where PBT have found utmost application. Nowadays, PBT is also being used in the treatment of other malignancies such as carcinoma prostate, carcinoma breast, head and neck malignancies, and gastrointestinal (GI) malignancies. Despite advantages of PBT, there is not only a high cost of setting up of PBT centers but also a lack of definitive phase-III data. Therefore, we review the role of PBT in current day practice of oncology to bring out the nuances that must guide the practice to choose suitable patients for PBT.
Collapse
Affiliation(s)
- Gagan Saini
- Department of Radiation Oncology, MAX Super Speciality Hospital Patparganj and Vaishali, New Delhi, India
| | - Rashmi Shukla
- Department of Radiation Oncology, MAX Super Speciality Hospital Patparganj and Vaishali, New Delhi, India
| | - Kanika S. Sood
- Department of Radiation Oncology, Dharamshila Narayana Superspeciality Hospital, New Delhi, India
| | - Sujit K. Shukla
- Department of Radiation Oncology, Vardhaman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
| | - Ritu Chandra
- Department of Radiation Oncology, MAX Super Speciality Hospital Patparganj and Vaishali, New Delhi, India
| |
Collapse
|
45
|
Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy. Cells 2020; 9:cells9061408. [PMID: 32517054 PMCID: PMC7349914 DOI: 10.3390/cells9061408] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 05/28/2020] [Accepted: 06/01/2020] [Indexed: 12/27/2022] Open
Abstract
One of the driving forces of carcinogenesis in humans is the aberrant activation of receptors; consequently, one of the most promising mechanisms for cancer treatment is receptor inhibition by chemotherapy. Although a variety of cancers are initially susceptible to chemotherapy, they eventually develop multi-drug resistance. Anti-tumor agents overcoming resistance and acting through two or more ways offer greater therapeutic benefits over single-mechanism entities. In this study, we report on a new family of bifunctional compounds that, offering the possibility of dual action (drug + radiotherapy combinations), may result in significant clinical benefits. This new family of compounds combines two fragments: the drug fragment is a lapatinib group, which inhibits the tyrosine kinase receptor activity, and an icosahedral boron cluster used as agents for neutron capture therapy (BNCT). The developed compounds were evaluated in vitro against different tyrosine kinase receptors (TKRs)-expressing tumoral cells, and in vitro–BNCT experiments were performed for two of the most promising hybrids, 19 and 22. We identified hybrid 19 with excellent selectivity to inhibit cell proliferation and ability to induce necrosis/apoptosis of glioblastoma U87 MG cell line. Furthermore, derivative 22, bearing a water-solubility-enhancing moiety, showed moderate inhibition of cell proliferation in both U87 MG and colorectal HT-29 cell lines. Additionally, the HT-29 cells accumulated adequate levels of boron after hybrids 19 and 22 incubations rendering, and after neutron irradiation, higher BNCT-effects than BPA. The attractive profile of developed hybrids makes them interesting agents for combined therapy.
Collapse
|
46
|
Wu D, Zhao Z, Wang N, Zhang X, Yan H, Chen X, Fan Y, Liu W, Liu X. Fluorescence imaging-guided multifunctional liposomes for tumor-specific phototherapy for laryngeal carcinoma. Biomater Sci 2020; 8:3443-3453. [PMID: 32412569 DOI: 10.1039/d0bm00249f] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Reliable diagnosis and efficient targeted therapy are important and may lead to the effective treatment of laryngeal carcinoma. Multifunctional nano-theranostic agents demonstrate great potential in tumor theranostic applications. Thus, herein, we report novel targeting multifunctional theranostic nanoparticles, internalized RGD (iRGD)-modified indocyanine green (ICG) encapsulated liposomes (iLIPICG), for imaging-guided photothermal therapy (PTT) and photodynamic therapy (PDT) for the treatment of laryngeal carcinoma. The iRGD-PEG-DSPE lipid endowed iLIPICG with high affinity for tumor vascular targeting, tumor-penetration and tumor cell targeting. The in vivo results showed that iLIPICG exhibited excellent blood circulation and tumor accumulation. iLIPICG could be spatially and temporally controlled, simultaneously producing hyperthermia and reactive oxygen species as well as a fluorescence-guided effect through ICG to ablate laryngeal carcinoma cells under irradiation from an 808 nm laser. iLIPICG generated synergistic photodynamic-photothermal cytotoxicity against Hep-2 cells, resulting in the efficient ablation of laryngeal carcinoma. Thus, the iLIPICG system provides a promising strategy to improve the precision imaging and effective phototherapy for the treatment of laryngeal carcinoma.
Collapse
Affiliation(s)
- Di Wu
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Lo YW, Lee JC, Hu YS, Li CY, Chen YL, Lin CS, Huang WS, Lin KH, Chen YW. The importance of optimal ROIs delineation for FBPA-PET before BNCT. Appl Radiat Isot 2020; 163:109219. [PMID: 32561058 DOI: 10.1016/j.apradiso.2020.109219] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 04/27/2020] [Accepted: 05/04/2020] [Indexed: 11/27/2022]
Abstract
One of the eligible criteria for patients to receive boron neutron capture therapy (BNCT) is based on the tumour-to-normal ratio (T/N) measured by FBPA-PET. However, there is no standard protocol for normal region-of-interested delineation. With comparison of contralateral cerebrum, our study revealed the consistency (p < 0.05) and high feasibility using the cerebellum as an alternative normal tissue baseline because of its homogeneous uptake. Following RECIST version 1.1, the standard-operating-procedure (SOP) for the BNCT fulfilled the expected tumour response and tumour shrinkage rate (p < 0.05). Our modified procedure can provide more precise information for BNCT within a reasonable time.
Collapse
Affiliation(s)
- Yi-Wen Lo
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Jia-Cheng Lee
- Division of Radiotherapy, Department of Oncology Medicine, Taipei Veterans General Hospital, Taiwan
| | - Yong-Sin Hu
- Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan
| | - Chien-Ying Li
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Yi-Lun Chen
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Chi-Shuo Lin
- Division of Radiotherapy, Department of Oncology Medicine, Taipei Veterans General Hospital, Taiwan
| | - Wen-Sheng Huang
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Ko-Han Lin
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
| | - Yi-Wei Chen
- Division of Radiotherapy, Department of Oncology Medicine, Taipei Veterans General Hospital, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan.
| |
Collapse
|
48
|
Ali F, S Hosmane N, Zhu Y. Boron Chemistry for Medical Applications. Molecules 2020; 25:E828. [PMID: 32070043 PMCID: PMC7071021 DOI: 10.3390/molecules25040828] [Citation(s) in RCA: 99] [Impact Index Per Article: 24.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Revised: 02/07/2020] [Accepted: 02/11/2020] [Indexed: 12/13/2022] Open
Abstract
Boron compounds now have many applications in a number of fields, including Medicinal Chemistry. Although the uses of boron compounds in pharmacological science have been recognized several decades ago, surprisingly few are found in pharmaceutical drugs. The boron-containing compounds epitomize a new class for medicinal chemists to use in their drug designs. Carboranes are a class of organometallic compounds containing carbon (C), boron (B), and hydrogen (H) and are the most widely studied boron compounds in medicinal chemistry. Additionally, other boron-based compounds are of great interest, such as dodecaborate anions, metallacarboranes and metallaboranes. The boron neutron capture therapy (BNCT) has been utilized for cancer treatment from last decade, where chemotherapy and radiation have their own shortcomings. However, the improvement in the already existing (BPA and/or BSH) localized delivery agents or new tumor-targeted compounds are required before realizing the full clinical potential of BNCT. The work outlined in this short review addresses the advancements in boron containing compounds. Here, we have focused on the possible clinical implications of the new and improved boron-based biologically active compounds for BNCT that are reported to have in vivo and/or in vitro efficacy.
Collapse
Affiliation(s)
- Fayaz Ali
- School of Pharmacy, Macau university of Science and Technology, Avenida Wai Long Taipa, Macau 999078, China;
| | - Narayan S Hosmane
- Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, IL 60115, USA
| | - Yinghuai Zhu
- School of Pharmacy, Macau university of Science and Technology, Avenida Wai Long Taipa, Macau 999078, China;
| |
Collapse
|
49
|
Barth RF, Grecula JC. Boron neutron capture therapy at the crossroads - Where do we go from here? Appl Radiat Isot 2019; 160:109029. [PMID: 32351210 DOI: 10.1016/j.apradiso.2019.109029] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Revised: 11/15/2019] [Accepted: 12/23/2019] [Indexed: 02/03/2023]
Abstract
As elegant as is the concept upon which Boron Neutron Capture Therapy (BNCT) is based, unfortunately it has not gained widespread acceptance by the physicians who are treating cancer patients on a daily basis. The question is why? Very simply put, the clinical results obtained in treating patients with high grade gliomas and recurrent tumors of the head and neck region have not been convincing enough to produce more interest in BNCT as a cancer treatment modality. There are a variety of reasons for this, one of the most important of which has been its dependency on nuclear reactors as neutron sources. With the advent of accelerator based neutron sources (ABNS), this hopefully will be addressed. If the results obtained from ongoing and soon to be initiated clinical trials can at least demonstrate equivalency to those obtained with nuclear reactors, this should address the first problem. The second problem relates to boron delivery agents, and despite the considerable efforts of chemists and biologists over the past 50 years, there are only two drugs that currently are being used clinically, sodium borocaptate (BSH) and boronophenylalanine (BPA). It is widely recognized that these two drugs are less than ideal. Perhaps new and more effective boron delivery agents will finally appear on the scene, but barring that, we will address the question of what can be done now to make BNCT a more effective cancer treatment modality.
Collapse
Affiliation(s)
- Rolf F Barth
- Department of Pathology, The Ohio State University, Columbus, OH, 43210, USA.
| | - John C Grecula
- Department of Radiation Oncology, The Ohio State University, Columbus, OH, 43210, USA
| |
Collapse
|
50
|
Yuan TZ, Xie SQ, Qian CN. Boron neutron capture therapy of cancer: Critical issues and future prospects. Thorac Cancer 2019; 10:2195-2199. [PMID: 31679175 PMCID: PMC6885431 DOI: 10.1111/1759-7714.13232] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 10/08/2019] [Indexed: 01/22/2023] Open
Affiliation(s)
- Tai-Ze Yuan
- Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, China
| | - Shu-Qing Xie
- Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, China
| | - Chao-Nan Qian
- Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, China.,Department of Nasopharyngeal carcinoma, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| |
Collapse
|